Anti-inflammatory effects of oral prednisolone at stable state in people treated with mepolizumab: a proteomic and bulk transcriptomics analysis

I. Howell¹, F. Yang^{2,3}, V. Brown⁴, J. Cane¹, E. Marchi¹, A Azim⁵, J. Busby⁴, P.J. McDowell⁴, S.E. Diver⁶, C. Borg¹, L. G. Heaney⁴, I. D. Pavord¹, C. E. Brightling⁶, R. Chaudhuri², T.S.C. Hinks¹

- Respiratory Medicine Unit, Experimental Medicine Division, Nuffield Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom & National Institute for Health Research Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK
- 2. University of Glasgow, Glasgow, UK.
- 3. The National Heart and Lung Institute, Imperial college London, London, UK
- 4. Queen's University Belfast, Belfast, UK.
- Clinical and Experimental Sciences, University of Southampton Faculty of Medicine, Sir Henry Wellcome Laboratories and NIHR Southampton Respiratory Biomedical Research Unit, Southampton University, Southampton, UK
- 6. Institute for Lung Health, Leicester NIHR BRC, University of Leicester, Leicester, UK.

Abstract

Mepolizumab is an anti-interleukin-5 monoclonal antibody treatment for severe eosinophilic asthma (SEA) that reduces asthma exacerbations. Residual airway inflammation on mepolizumab may lead to persistent exacerbations. Oral corticosteroids have broad anti-inflammatory effects and remain the main treatment for these residual exacerbations. Our study aimed to explore the nature and corticosteroid-responsiveness of airway inflammation after mepolizumab treatment to find potentially treatable inflammatory mechanisms.

The MAPLE trial was a multi-centre, randomized, double-blind, placebo-controlled, crossover study of 2 weeks of high-dose oral prednisolone treatment at stable state in patients treated with mepolizumab for SEA. We analysed sputum and plasma samples from the MAPLE trial using high-throughput Olink[®] proteomics. We also analysed plasma microRNA, sputum proteins using ELISA, and nasal mucosal bulk RNA sequencing.

In patients receiving mepolizumab, prednisolone significantly downregulated sputum proteins related to type-2 inflammation and chemotaxis including IL-4, IL-5, IL-13, CCL24, CCL26, EDN, CCL17, CCL22, OX40 receptor, FCER2, and the ST2 receptor. Prednisolone also downregulated cell adhesion molecules, prostaglandin synthases, mast cell tryptases, MMP1, MMP12, and neuroimmune mediators. Tissue repair and neutrophilic pathways were upregulated. Type-2 proteins were also downregulated in plasma, combined with IL-12, IFN-γ, and IP-10. IL-10 and amphiregulin were upregulated. In the nasal transcriptome, prednisolone suppressed genes involved in leucocyte chemotaxis, mast cell tryptase, 15-lipoxygenase and *MMP12*. By contrast, mepolizumab differentially regulated only Galectin-10 in plasma and no sputum proteins, and in nasal tissue affected genes related to cilia, keratinisation, extracellular matrix formation, and IL-4/13 signalling.

At stable state, prednisolone has broad anti-inflammatory effects on top of mepolizumab.

Introduction

Oral corticosteroids (OCS) are a widely prescribed treatment for asthma exacerbations¹. Clinical evidence for OCS at exacerbation is based on trials demonstrating a reduction in relapse and accelerated symptom resolution². Biologically, OCS reduce eosinophilic inflammation, evidenced by a rapid decline in blood eosinophils through apoptosis and inhibition of interleukin-5 (IL-5)-induced production by the bone marrow^{3,4}. However, OCS have broader anti-inflammatory effects that may also be clinically important. The placebo-controlled BIOAIR study identified inflammatory proteins downregulated by prednisolone in both mild/moderate and severe asthma at stable state in plasma⁵. These included chemokines and proteins involved in recruiting eosinophils to the airways⁶. But antiinflammatory effects of OCS also extend to the airway mucosa. A placebo-controlled human bronchoscopy study in stable, moderate asthma found that prednisolone reduced airway eosinophilia, tryptase single-positive mast cells, IL-4, IL-5, and CD3+ T lymphocytes⁷.

Systemic monoclonal antibody therapy (mAb) has revolutionised the treatment of severe eosinophilic asthma. Placebo-controlled trials of mepolizumab, an anti-IL5 mAb, demonstrated approximately a 50% reduction in the annualised exacerbation rate and maintenance OCS dose⁸. This is important because repeated OCS exposure is associated with serious acute and chronic adverse effects⁹. However, some patients continue to have asthma exacerbations despite mepolizumab therapy. The MEX study showed that roughly half of these events were sputum eosinophil high, which suggests that inflammatory pathways beyond IL-5 may remain upregulated and clinically relevant in some people¹⁰. The nature of these pathways is not understood.

The MAPLE trial was an exploratory, multi-centre, randomized, double-blind, placebo-controlled, crossover study of prednisolone in adults treated with mepolizumab at stable state. There was no significant clinical improvement with prednisolone¹¹. In this manuscript, we report the planned transcriptomic and proteomic analysis of sputum, plasma, and nasal samples from the MAPLE trial, to test the hypothesis that prednisolone exerts additional anti-inflammatory effects to mepolizumab at stable state.

Methods

Study design

The MAPLE study population and design were described previously¹¹. Briefly, participants were recruited before or after starting mepolizumab for usual clinical care. All participants received at least 12 weeks of mepolizumab, and were OCS-free for over 4 weeks, before they were randomised (1:1) to prednisolone (0.5 mg/kg/d, maximum dose of 40 mg/d, 14 ± 2 days) followed by a 4-week washout

period and then matched placebo or *vice versa* (figure 1). Prednisolone adherence was confirmed with tablet counts and serum prednisolone and cortisol levels.

Sputum, blood, and nasal sampling and processing

Figure 1 describes the trial sampling.

Sputum was induced using hypertonic saline (see Appendix). Samples were transferred to the laboratory within 2 hours for initial processing. Sputum plugs were selected from saliva, weighed, and centrifuged in phosphate-buffered saline (PBS) at 790 g for 10 minutes at 4°C. Samples were aliquoted and stored at -80°C in cryovials until further processing.

Nasal scrape samples were obtained using disposable curettes from the inferior turbinate under direct visualisation (see Appendix). Cells were stored in an RNAprotect cell reagent at -80 °C until processing.

Olink[®] proteomic analysis of sputum and plasma samples

Sputum supernatant and plasma from all visits were analysed by Olink[®] Explore 1536 proximity extension assays for 1536 proteins. Olink[®] hybridises DNA oligonucleotide-labelled antibody pairs to proteins, extends oligonucleotides by DNA polymerase, quantifies them with next generation sequencing, and log2 transforms concentrations to a normalised protein expression (NPX) value.

Statistical analyses were performed with the Olink[®] Analyze package in R, according to manufacturer's guidance. We determined the effect of prednisolone *versus* placebo on paired sputum and plasma proteins using a change from baseline analysis in a linear mixed effects model¹². The type and sequence of treatment were fixed effects and participant ID was the random effect, with Benjamini-Hochberg (BH) correction for multiplicity of testing. An FDR <0.05 and absolute log2fold change >0.5 was considered significant. The effect of mepolizumab on sputum and serum proteins was determined using paired t-tests with BH correction. Pathway analysis was performed using Cluster Profiler, heatmaps using Pheatmap, and correlation matrices using Corrplot.

ELISA of sputum samples

Sputum supernatants from all visits were assayed using the Ella[®] ELISA platform (Bio-Techne) for 15 analytes: IL-17E/IL-25, IL-1 α , IL-1 β , IL-2Ra, IL-33, IL-6, IL-6R, MPO, IL-3, YKL-40, IL-1RA, GM-CSF, TSLP, EDN, IL1R1. The effect of prednisolone *versus* placebo was analysed on paired samples using linear mixed effects models, and the effect of mepolizumab using paired t-tests, with BH correction (FDR<0.05).

Bulk transcriptomics of nasal tissue samples

RNA was extracted using Qiagen RNeasy mini kits. Samples with RNA integrity number <5 and/or undetectable RNA quantity were excluded from sequencing. RNA poly A sequencing was performed

by Novogene using Illumina Novaseq PE150. Gene alignment and quantification was performed by Novogene.

Differentially expressed genes were identified in DESeq2 using paired t-tests on gene count data between post-treatment placebo and prednisolone samples, and pre-mepolizumab to post-mepolizumab (post-placebo) samples. These underwent BH correction. An FDR <0.1 and absolute log2fold change >0.5 was considered significant.

MicroRNA sequencing of plasma samples

Plasma samples underwent Illumina TruSeq Small RNA analysis, read alignment, and quantification by Q² solutions[®]. Precursor and mature miRNA read counts were analysed for differential expression using a linear mixed effects model for the placebo *versus* prednisolone comparison, and paired t-tests comparing pre- to post-mepolizumab in DESeq2. These underwent BH correction. An FDR <0.1 and absolute log2fold change >0.5 was considered significant.

Sample size

As this was a secondary analysis on a trial powered on clinical endpoints, a power calculation was not performed. Findings are exploratory and descriptive.

Results

Comparison between prednisolone and placebo

Olink[®]

16 participants (supplementary table 1 and 2) had paired sputum samples before and after prednisolone and placebo in the crossover trial for Olink[®] analysis. 158 proteins were significantly downregulated by prednisolone and 51 proteins were significantly upregulated (figure 2, table 1, supplementary table 3 and 4).

Pathway analysis in sputum showed key downregulated biological processes including chemokine pathways crucial to subepithelial Th2/Tc2 cell, eosinophil and mast cell recruitment, and pathways related to IL-4 activity. Highly downregulated proteins related to type-2 inflammation and chemotaxis included IL-4, IL-13, IL-5, eotaxins 2 and 3 (CCL24 and CCL26), the chemokines CCL17 (TARC) and CCL22, OX40 receptor (TNFRSF4), TIMD4, the low-affinity IgE receptor FCER2, and the ST2 receptor for IL-33 (IL1RL1). Cell adhesion molecules involved in granulocyte trafficking, such as ICAM1, VCAM, TIE1, and e-selectin (SELE), were also downregulated. A reduction in the prostaglandin synthases PTGDS and HPGDS, SIGLEC6, and carboxypeptidase B1 (CPB1) that is closely related to mast cell tryptase (CPA3, not in the Olink[®] panel) suggests a downregulation of mast cell activity. Likewise, mast cell alpha-1/beta-1 tryptase (TPSAB1) was numerically reduced by over 50% though non-significant (adjusted p = 0.07). Proteins related to NF-kappaB (NF- κ B) signalling were downregulated, including CD30 (TNFRSF8), CD69, and RANKL (TNFSF11), as were proteins related to tissue remodelling, including MMP12 and MMP1. NCAM1, NCAN, and GDNF, mediators of neuroimmune activity, were also downregulated.

Key upregulated pathways in sputum related to tissue repair and neutrophilic inflammation, such as IL-1β, IL-17C, and IL-22RA1. FKBP5, a classical hallmark of corticosteroid exposure, was upregulated.

Unsupervised clustering of the 40 proteins most downregulated in sputum after prednisolone revealed heterogeneity between individuals (n=16) in the anti-inflammatory effects of prednisolone (figure 2D). We analysed the correlation between clinical data and change in protein expression for biologically important sputum proteins after prednisolone (figure 3). This showed a reduction in sputum IL-5 and prostaglandin D synthase had an inverse correlation with FEV₁, change in RANKL was correlated with change in FeNO, and IL-33 correlated with the downregulation of other type-2 cytokines and chemokines, but TSLP did not.

25 participants (supplementary table 1 and 2) had paired plasma samples before and after prednisolone and placebo in the crossover trial analysed by Olink[®]. 74 proteins were significantly

downregulated by prednisolone and 53 proteins were significantly upregulated (figure 4, table 2, supplementary table 5 and 6).

The pathway analysis in plasma corresponded to that in sputum, showing downregulated biological processes included chemokines, type-2 inflammation pathways, and granulocyte trafficking. Relevant downregulated proteins included IL-4, eotaxin-3 (CCL26), CCL17 (TARC), CCL22, CCL19, CD83, OX40 receptor (TNFRSF4), ICAM1, VCAM. Proteins linked to remodelling such as MMP12, MMP1, and MMP10 were reduced. Proteins related to NF-κB signalling were also downregulated, including CD30 (TNFRSF8) and B-cell activating factor (TNFSF13B). There was a decrease in plasma IL-6. Additionally, plasma IL-12 activity, and associated plasma IFN-γ and IP-10 (CXCL10) levels, were significantly reduced by prednisolone.

Key upregulated processes in plasma included IL-10 and amphiregulin (AREG), important in tissue repair. MMP3 and FKBP5 were raised by prednisolone; both are previously associated with corticosteroid exposure^{13,14}.

Unsupervised clustering of change in NPX after prednisolone and placebo in the 40 most downregulated plasma proteins suggested the anti-inflammatory effects of prednisolone in serum were more homogeneous compared to sputum (n=25) (figure 4D).

ELISA

16 participants provided sputum samples before and after prednisolone and placebo in the crossover trial that underwent ELISA. Eosinophil-derived neurotoxin (EDN) was significantly reduced after prednisolone (-1,180 ng/ml, adjusted p = 0.0001), while IL-1RA was significantly increased (16.9 ng/ml, adjusted p = 0.045). All other assays did not significantly change (supplementary figure 1, supplementary table 7).

Nasal tissue transcriptomics

6 participants provided good quality nasal tissue RNA post-prednisolone and post-placebo. 28 genes were significantly downregulated, and 3 genes significantly upregulated (Supplementary figure 2, supplementary table 8). Key genes suppressed by prednisolone included those involved in leucocyte chemotaxis (*CXCL2, CXCL3, CX3CR1, CXCL5*), mast cell tryptase (*TPSB2*), gasdermin D (*GSDMD*), 15-lipoxygenase (*ALOX15*), and matrix metalloproteinase 12 (*MMP12*).

Plasma microRNA

25 participants had paired plasma tested for miRNA. There were 19 significantly differentially expressed precursor miRNAs after prednisolone. However, there were no significantly differentially expressed mature miRNAs (supplementary table 9).

Comparison between pre-mepolizumab and post-mepolizumab

Olink[®]

Paired sputum samples from 10 participants were analysed by Olink[®] before and after starting mepolizumab. There were no significantly changed proteins. To understand the trend in pathways affected by mepolizumab, we performed pathway analysis using FDR <0.15 and abs log2fold >0.5. Upregulated pathways included MAPK signalling and regulation of leucocyte migration (supplementary figure 3).

Paired plasma samples from 10 participants were analysed by Olink[®] before and after starting mepolizumab. Galectin-10 (CLC) was the only significantly differing protein in plasma, reduced by 70%. Pathway analysis using FDR <0.15 and abs log2fold >0.2 showed mepolizumab initiation downregulated pathways related to lymphoid cell interactions and IL-3, IL-5, and GM-CSF signalling (supplementary figure 4).

ELISA

There were no significant differences associated with mepolizumab initiation in any of the sputum proteins tested.

Nasal tissue transcriptomics

5 participants provided good quality nasal tissue RNA before and after mepolizumab treatment. 272 genes were significantly downregulated and 105 significantly upregulated (supplementary table 10 and 11). In pathway analysis downregulated genes were related to ciliary structure and function. Upregulated genes were related to keratinisation, extracellular matrix formation, tight junctions, and IL-4 and IL-13 signalling pathways (figure 5).

Plasma microRNA

There were no significant differentially expressed precursor or mature miRNAs associated with mepolizumab initiation.

Discussion

Using a combination of high-throughput proteomics and bulk transcriptomics analysis of airway and blood samples at stable state, we found that oral prednisolone has extensive additional biological effects on top of mepolizumab.

The most striking effect of prednisolone on airway samples was the marked reduction in type-2 cytokines and chemokines (figure 6). Eotaxins, CCL17 and CCL22 are released by the airway epithelium and dendritic cells in response to IL-4 and TSLP. These chemokines have an important role in stimulating Th2/Tc2 cell and mast cell recruitment via CCR3 and CCR4 receptors. The resultant release of IL-4, IL-5, and IL-13 perpetuates Th2 cell differentiation, stimulates B cell maturation and production of IgE, and acts in concert with eotaxins, VCAM, ICAM1, E-selectin, and TIE1 to recruit eosinophils to the airway epithelium⁸. This self-perpetuating inflammation is analogous to an airway epithelial "magnet" recruiting effector granulocytes, analogous to "bombs"¹⁵. Our proteomic data demonstrate this process remains active and corticosteroid-responsive despite mepolizumab treatment, which selectively inhibits recruitment of eosinophils through IL-5. These findings are supported by the reduction of EDN in sputum, and CXCL2, CXCL3 and CXCL5 transcriptional suppression in nasal tissue.

Biological mechanisms underpinning these effects are complex. Corticosteroids impair dendritic cell maturation, downregulate IL-4 receptor expression, inhibit IL-4/IL-13 induced STAT6 signalling, and directly inhibit e-selectin, VCAM and ICAM1 expression¹⁶⁻¹⁹. Additionally, corticosteroids upregulate the production of IL-10, as observed in our plasma proteomics, which reduces Th2 cytokine production²⁰. Interestingly, the anti-inflammatory effects of prednisolone in the airway varied between individuals despite confirmed prednisolone adherence in all participants. This means that these inflammatory pathways were only active in some people at stable state, suggesting heterogeneity amongst the severe eosinophilic asthma phenotype.

Prednisolone also suppressed mast cell activity. Prostaglandin synthases (PTGDS, HPGDS) and Siglec-6 were reduced, and *15-lipooxygenase* was transcriptionally suppressed. Mast cell tryptase (CPA3) was not in the Olink[®] panel, but the related CPB1 which resides at the same gene locus as CPA3²¹, was significantly reduced. Additionally, the beta tryptase gene in mast cells (*TPSB2*) was transcriptionally suppressed in nasal tissue. Corticosteroids reduce mast cell signalling pathways and attenuate histamine release²². *Post-hoc* analysis of nasal transcriptome data in children suggested that mepolizumab may enhance mast cell and epithelial inflammation²³. If corticosteroid-responsive mast cell activation remains present in some individuals despite mepolizumab therapy, this may be clinically relevant due to mast cell mediated airway smooth muscle contraction, and may drive some residual exacerbations which occur despite effective eosinophil depletion.

Proteomics showed prednisolone reduced the matrix metalloproteinases MMP12 and MMP1 in sputum and plasma, which correlated with type-2 epithelial cytokines. Furthermore, MMP12 transcription was significantly downregulated in nasal tissue after prednisolone. MMP12 is produced by macrophages and bronchial epithelial cells²⁴. In murine models, it has been linked to airway remodelling via IL-13 dependent mechanisms^{25,26}. In humans, reduced *MMP12* expression due to a functional polymorphism was associated with improved pulmonary function²⁷. MMP1 expression is increased in the airways of people with asthma and is inversely associated with FEV₁²⁸. *In vitro*, MMP1 is induced via β3-integrin-mediated MAPK signalling leading to reduced smooth muscle contraction²⁹. Additionally, MMP1 is activated by mast cell tryptase, which generates pro-proliferative extracellular matrix³⁰. Our data suggest that IL-13 and mast cell-dependent MMP12 and MMP1 activation remain in some patients with asthma despite anti-IL5 treatment. The consequent potential effect on long-term lung function decline needs further investigation.

Prednisolone also significantly reduced GDNF and NCAM, mediators of neuroimmune activity, and these reductions correlated strongly with other type-2 inflammatory proteins. GDNF signals through the NCAM receptor³¹. *In vitro*, GDNF expression is increased in human airway smooth muscle cells in asthma and influences intracellular calcium responses³². In rat asthma models, GDNF expression was significantly higher than in controls and central sensitisation to GDNF injected in the lateral ventricle led to a significant increase in bronchial IL-4 and Th2 cells, and significant decrease in pulmonary function³³. GDNF may contribute to smooth muscle hyperreactivity, and we found it was corticosteroid responsive.

Corticosteroids can inhibit signalling through the Toll-like receptor (TLR) cascade, including tethering and inhibiting transcription factors such as NF-κB through glucocorticoid receptors³⁴. Our data suggest that components of NF-κB signalling were downregulated by prednisolone and, interestingly, this was associated with reduction in FeNO. This association is plausible because inducible nitric oxide synthase (NOS2) production is dependent on NF-κB signalling³⁵. The NOS2 protein was not in the Olink[®] panel so we cannot comment on its response to prednisolone. The mechanisms underpinning elevated FeNO in some people despite anti-IL5 treatment is of clinical interest. There was a suggestion in our proteomic and transcriptomic pathway analysis that MAPK – which is important in TLR signalling and transactivates STAT6^{36,37} – and IL-4/IL-13 signalling pathways were upregulated following mepolizumab initiation. We also found upregulation of ciliary and extracellular matrix genes in the nasal transcriptomics that may represent epithelial repair mechanisms. This would be consistent with previous nasal transcriptome data in mepolizumab-treated children where increased expression of epithelial signalling and extracellular matrix pathways were associated with more exacerbations, likely due to increased cycles of epithelial repair post-exacerbation³⁸. In adults, nasal epithelial cytokine and

alarmin activation (IL-4, TSLP, IL-33) after mepolizumab treatment was associated with non-responder status³⁹, suggesting a clinically relevant subgroup of severe eosinophilic asthma where inflammation is driven more by alarmins and the IL-4/13 pathway than by IL-5-mediated eosinophilia. As this epithelial signalling pathway was steroid-responsive, we speculate this inflammation could also be targeted using anti-IL4R α , anti-TSLP, anti-IL33, or JAK inhibitors.

Our study has several strengths. Firstly, the crossover study design allowed paired comparison of biological effects of prednisolone *versus* placebo within each participant, thus avoiding interparticipant variability. Secondly, high-throughput multiomic analyses of both airway and plasma samples enabled extensive exploration of prednisolone effects in both compartments. The only previous such placebo-controlled proteomic study of prednisolone in asthma analysed only plasma⁵. Thirdly, the 4-week washout and objective measurement of plasma prednisolone levels in participants provide confidence that effects are attributable to treatment.

The main limitation of our study was modest sample size, particularly for nasal transcriptomic analysis due to low quality nasal scrape samples. Whilst the paired crossover design improved power for prednisolone *versus* placebo assessment, the lack of placebo control limited assessment of mepolizumab effects. Our findings are exploratory and should be replicated in future cohorts. Furthermore, whilst sampling occurred within a clinical trial, allowing close comparison of biological and clinical effects, our study was undertaken at stable state without long-term follow-up during exacerbations, so we did not detect significant clinical changes.

The advent of anti-IL5 monoclonal antibody therapy has dramatically altered management of severe asthma. Patients rely less on oral corticosteroids, with their extensive associated toxicity, to achieve asthma control. However, severe asthma is a heterogeneous condition. Our data demonstrate that some individuals have IL-5-independent airway epithelial inflammatory pathways which remain active and are corticosteroid-responsive. The limited effect of prednisolone on symptoms and lung function in MAPLE suggests that these residual corticosteroid responsive pathways play a minor functional role in stable patients treated with mepolizumab. However, the effect of this persistent inflammation on key asthma outcomes such as long-term lung function decline and risk of exacerbations is unknown. Prospective studies are required to determine if there are clinically relevant anti-inflammatory effects of prednisolone at exacerbation in people treated with asthma monoclonal antibodies⁴⁰.

Contributors

RC, LGH, IDP, CEB, FY, JB contributed to conceptualisation and design of the protocol. FY, JPM, SED, CB contributed to acquisition of study data. Lab samples were processed by IH, VB and JC. Data were

analysed by IH and EM. IH and EM have accessed and verified the data. IH and TSCH drafted this submission which was approved by all authors.

Declaration of interests

IH has received a conference travel grant from GSK.

FY and SED have received speaker fees from AstraZeneca.

JC, VB, and EM report no declarations of interest.

AA is currently an employee of AZ.

PJM has received support to attend educational meetings from Chiesi.

JB has received personal fees from NuvoAir, and a research grant to his Institute from AstraZeneca, outside the submitted work.

CB has received speakers fees from AZ and GSK and has received advisory board fees from AZ.

LH has received grants from GSK, Astra Zeneca, Roche/Genentech, has given lectures supported by Astra Zeneca, Sanofi, Circassia, GlaxoSmithKline, has received travel grants from AstraZeneca and GSK, and has honoraria for Advisory Board Meetings from Novartis, Roche/Genentech, GSK, Teva and Celltrion.

IDP has received speaker's honoraria for speaking at sponsored meetings from Astra Zeneca, Boehringer Inglehiem, Aerocrine, Almirall, Novartis, Teva, Chiesi, Sanofi/Regeneron, Menarini and GSK and payments for organising educational events from AZ, GSK, Sanofi/Regeneron and Teva. He has received honoraria for attending advisory panels with Genentech, Sanofi/Regeneron, Astra Zeneca, Boehringer Ingelheim, GSK, Novartis, Teva, Merck, Circassia, Chiesi and Knopp and payments to support FDA approval meetings from GSK. He has received sponsorship to attend international scientific meetings from Boehringer Ingelheim, GSK, Astra Zeneca, Teva and Chiesi. He has received a grant from Chiesi to support a phase 2 clinical trial in Oxford. He is co-patent holder of the rights to the Leicester Cough Questionnaire and has received payments for its use in clinical trials from Merck, Bayer and Insmed. In 2014-5 and 2019-20 he was an expert witness for a patent dispute involving Astra Zeneca and Teva.

CEB has received grants and consultancy fees from 4D Pharma, Areteia, AstraZeneca, Chiesi, Genentech, GlaxoSmithKline, Mologic, Novartis, Regeneron Pharmaceuticals, Roche and Sanofi.

RC has received lecture fees from GSK, AZ, Teva, Chiesi, Sanofi and Novartis; honoraria for Advisory Board Meetings from GSK, AZ and Celltrion; sponsorship to attend international scientific meetings from Chiesi, Sanofi and GSK and a research grant to her Institute from AZ for a UK multi-centre study.

TSCH has received grants from the Wellcome Trust, grants from The Guardians of the Beit Fellowship, and grants from the NIHR Oxford Biomedical Research Centre during the conduct of the study; and grants from Pfizer Inc., grants from University of Oxford, personal fees from Astra Zeneca, personal fees from TEVA, personal fees from Peer Voice outside the submitted work.

Data sharing

Anonymised patient level data analysed and presented in this study are available from the corresponding author on reasonable request, providing the request meets local ethical and research governance criteria after publication. Data will be available immediately after publication for 10 years.

Funding

This study was funded jointly by the Medical Research Council (MRC) UK (MR/M016579/1) and industrial partners within the MRC Refractory Asthma Stratification Programme consortium and by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). Proteomics and transcriptomics analysis was funded by GSK (ID: 215294). TSCH is supported by a Wellcome Trust Fellowship (211050/Z/18/z). All authors had full access to the full data in the study and accept responsibility to submit for publication.

Acknowledgements

The authors are grateful to all the participants who volunteered and to the clinical and research teams at all the participating centres. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

References

1. Levy ML, Bacharier LB, Bateman E, et al. Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update. NPJ Prim Care Respir Med 2023;33:7.

2. Rowe BH, Spooner CH, Ducharme FM, Bretzlaff JA, Bota GW. Corticosteroids for preventing relapse following acute exacerbations of asthma. Cochrane Database Syst Rev 2007:Cd000195.

3. Sahid El-Radhi A, Hogg CL, Bungre JK, Bush A, Corrigan CJ. Effect of oral glucocorticoid treatment on serum inflammatory markers in acute asthma. Arch Dis Child 2000;83:158-62.

4. Moran AM, Ramakrishnan S, Borg CA, et al. Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma. Am J Respir Crit Care Med 2020;202:1314-6.

5. Sparreman Mikus M, Kolmert J, Andersson LI, et al. Plasma proteins elevated in severe asthma despite oral steroid use and unrelated to Type-2 inflammation. Eur Respir J 2022;59.

6. Schleimer RP, Bochner BS. The effects of glucocorticoids on human eosinophils. J Allergy Clin Immunol 1994;94:1202-13.

7. Bentley AM, Hamid Q, Robinson DS, et al. Prednisolone treatment in asthma. Reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa. Am J Respir Crit Care Med 1996;153:551-6.

8. Howell I, Howell A, Pavord ID. Type 2 inflammation and biological therapies in asthma: Targeted medicine taking flight. J Exp Med 2023;220.

9. Skov IR, Madsen H, Henriksen DP, Andersen JH, Pottegård A, Davidsen JR. Low-dose oral corticosteroids in asthma associates with increased morbidity and mortality. Eur Respir J 2022;60.

10. McDowell PJ, Diver S, Yang F, et al. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study. Lancet Respir Med 2021;9:1174-84.

11. Yang F, Busby J, Heaney LG, et al. Corticosteroid Responsiveness Following Mepolizumab in Severe Eosinophilic Asthma-A Randomized, Placebo-Controlled Crossover Trial (MAPLE). J Allergy Clin Immunol Pract 2022;10:2925-34.e12.

12. Mehrotra DV. A recommended analysis for 2 × 2 crossover trials with baseline measurements. Pharm Stat 2014;13:376-87.

13. James A, Kolmert J, Wheelock C, et al. Increased serum MMP-3 in severe asthma is associated with oral steroid use; data from U-BIOPRED and BIOAIR cohorts. European Respiratory Journal 2017;50:PA580.

14. Jääskeläinen T, Makkonen H, Palvimo JJ. Steroid up-regulation of FKBP51 and its role in hormone signaling. Curr Opin Pharmacol 2011;11:326-31.

15. Couillard S, Pavord ID, Heaney LG, Petousi N, Hinks TSC. Sub-stratification of type-2 high airway disease for therapeutic decision-making: A 'bomb' (blood eosinophils) meets 'magnet' (FeNO) framework. Respirology 2022;27:573-7.

16. Elftman MD, Norbury CC, Bonneau RH, Truckenmiller ME. Corticosterone impairs dendritic cell maturation and function. Immunology 2007;122:279-90.

17. So EY, Kim SH, Park HH, Cho BS, Lee CE. Corticosteroid inhibits IL-4 signaling through downregulation of IL-4 receptor and STAT6 activity. FEBS Lett 2002;518:53-9.

18. Cronstein BN, Kimmel SC, Levin RI, Martiniuk F, Weissmann G. A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc Natl Acad Sci U S A 1992;89:9991-5.

19. Atsuta J, Plitt J, Bochner BS, Schleimer RP. Inhibition of VCAM-1 expression in human bronchial epithelial cells by glucocorticoids. Am J Respir Cell Mol Biol 1999;20:643-50.

20. Ogawa Y, Duru EA, Ameredes BT. Role of IL-10 in the resolution of airway inflammation. Curr Mol Med 2008;8:437-45.

21. Atiakshin D, Kostin A, Trotsenko I, Samoilova V, Buchwalow I, Tiemann M. Carboxypeptidase A3-A Key Component of the Protease Phenotype of Mast Cells. Cells 2022;11.

22. Oppong E, Flink N, Cato AC. Molecular mechanisms of glucocorticoid action in mast cells. Mol Cell Endocrinol 2013;380:119-26.

23. Gaberino C, Segnitz RM, Cox M, et al. Mepolizumab Alters Regulation of Airway Type-2 Inflammation in Urban Children with Asthma by Disrupting Eosinophil Gene Expression but Enhancing Mast Cell and Epithelial Pathways. Journal of Allergy and Clinical Immunology 2023;151:AB125.

24. Lavigne MC, Thakker P, Gunn J, et al. Human bronchial epithelial cells express and secrete MMP-12. Biochemical and biophysical research communications 2004;324:534-46.

25. Pouladi MA, Robbins CS, Swirski FK, et al. Interleukin-13–dependent expression of matrix metalloproteinase-12 is required for the development of airway eosinophilia in mice. American journal of respiratory cell and molecular biology 2004;30:84-90.

26. Lanone S, Zheng T, Zhu Z, et al. Overlapping and enzyme-specific contributions of matrix metalloproteinases-9 and-12 in IL-13–induced inflammation and remodeling. The Journal of clinical investigation 2002;110:463-74.

27. Hunninghake GM, Cho MH, Tesfaigzi Y, et al. MMP12, lung function, and COPD in high-risk populations. N Engl J Med 2009;361:2599-608.

28. Cataldo DD, Gueders M, Munaut C, et al. Matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases mRNA transcripts in the bronchial secretions of asthmatics. Lab Invest 2004;84:418-24.

29. Rogers NK, Clements D, Dongre A, Harrison TW, Shaw D, Johnson SR. Extra-cellular matrix proteins induce matrix metalloproteinase-1 (MMP-1) activity and increase airway smooth muscle contraction in asthma. PLoS One 2014;9:e90565.

30. Naveed S-u-n, Clements D, Jackson DJ, et al. Matrix Metalloproteinase-1 Activation Contributes to Airway Smooth Muscle Growth and Asthma Severity. American Journal of Respiratory and Critical Care Medicine 2017;195:1000-9.

31. Paratcha G, Ledda F, Ibáñez CF. The neural cell adhesion molecule NCAM is an alternative signaling receptor for GDNF family ligands. Cell 2003;113:867-79.

32. Bhallamudi S, Roos BB, Teske JJ, et al. Glial-derived neurotrophic factor in human airway smooth muscle. J Cell Physiol 2021;236:8184-96.

33. Wang X, Wang Y, Chen X, et al. The central glial cell line-derived neurotrophic factor (GDNF) regulates pulmonary function in asthmatic rats. Ann Transl Med 2023;11:113.

34. Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol 2017;17:233-47.

35. Taylor BS, de Vera ME, Ganster RW, et al. Multiple NF-kappaB enhancer elements regulate cytokine induction of the human inducible nitric oxide synthase gene. J Biol Chem 1998;273:15148-56.

36. Peroval M, Boyd A, Young J, Smith A. A Critical Role for MAPK Signalling Pathways in the Transcriptional Regulation of Toll Like Receptors. PloS one 2013;8:e51243.

37. Athari SS. Targeting cell signaling in allergic asthma. Signal Transduct Target Ther 2019;4:45.

38. Jackson DJ, Bacharier LB, Gergen PJ, et al. Mepolizumab for urban children with exacerbationprone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet 2022;400:502-11.

39. Rakkar K, Pang YL, Rajasekar P, et al. Mepolizumab induced changes in nasal methylome and transcriptome to predict response in asthma. medRxiv 2023:2023.05.18.23290155.

40. Howell I, Mahdi M, Bafadhel M, et al. Recovery of Breakthrough Asthma Attacks Treated With Oral Steroids While on Monoclonal Antibody Therapy: Protocol for a Prospective Observational Study (BOOST). JMIR Res Protoc 2023;12:e46741.

Tables

Table 1 – Summary of 25 most downregulated proteins by prednisolone versus placebo in sputum (Olink®)

Protein	Log2fold	Adjusted	Function	
	change	p value		
IL4	-3.37	4.81E-03	Stimulates proliferation of Th2 cells, B cell class switching to	
			IgE, and B cell differentiation to plasma cells.	
SERPINA9	-3.18	9.79E-06	Inhibits trypsin-like serine proteases.	
CCL24	-2.6	2.47E-04	Eotaxin-2. Induces eosinophil chemotaxis.	
MMP1	-2.6	1.44E-03	Breaks down interstitial collagens in the ECM.	
HLA-DRA	-2.46	1.88E-04	Presents peptides from extracellular proteins. Expressed on	
			B lymphocytes, dendritic cells and macrophages.	
TIE1	-2.44	3.70E-04	Cell surface protein that upregulates cell adhesion	
			molecules.	
CCL26	-2.43	5.02E-03	Eotaxin-3. Induces eosinophil and basophil chemotaxis.	
CCL22	-2.43	2.79E-02	Induces T cell, monocyte, and dendritic cell chemotaxis.	
CCL17	-2.37	6.68E-03	Induces T cell and granulocyte chemotaxis.	
GDNF	-2.29	3.96E-03	Promotes neuronal growth and survival.	
NCAM1	-2.18	6.60E-04	Mediates neurite outgrowth	
TIMD4	-2.16	8.56E-05	Involved in recognition of apoptotic cells for macrophage	
			phagocytosis.	
CCL13	-2.15	6.92E-03	Induces T cell, monocyte, and granulocyte chemotaxis.	
NCAN	-2.11	1.99E-04	Component of the ECM and involved in neuronal growth	
MCAM	-2.09	1.93E-04	Vascular endothelial cell adhesion molecule	
SELE	-2.07	3.74E-04	Endothelial adhesion molecule involved in leukocyte	
			recruitment.	
DOK2	-2.07	4.36E-03	Scaffolding protein for multimolecular signalling complexes.	
IL5	-2.06	2.89E-04	Mediates eosinophil production and activation	
GP1BA	-2.04	2.65E-04	Platelet surface glycoprotein	
VCAM1	-2.03	1.40E-03	Mediates adhesion of lymphocytes, eosinophils, and	
			basophils to the vascular endothelium.	
CPA2	-2	1.47E-02	Pancreatic carboxypeptidase.	
ARSB	-1.97	2.63E-03	Enzyme that breaks down glycosaminoglycans.	
MMP12	-1.97	6.09E-03	Breaks down elastin in the ECM.	
TNFRSF8	-1.95	5.57E-05	Expressed by T and B cells. Leads to activation of NF-KB.	
SPP1	-1.94	8.87E-04	Osteopontin. Anti-apoptotic factor in macrophages and T	
			cells. Also involved in leukocyte chemotaxis.	

Table 2 – Summary	<u>y of 25 most dow</u>	nregulated pr	oteins by	prednisolone	versus j	placebo in	<u>plasma</u>
(Olink®)							

Protein	Log2fold change	Adjusted p value	Function
IL4	-3.17	1.06E-05	See table 1

IL12A_IL12B	-2.24	1.55E-26	Encodes a subunit of IL-12. IL-12 is produced by dendritic cells, macrophages, and neutrophils to promote Th1 differentiation.	
IL12B	-2.09	3.88E-26	Encodes a subunit of IL-12.	
CRH	-1.46	3.80E-11	Corticotrophin-releasing hormone. Stimulates ACTH production.	
CCL22	-1.42	4.18E-21	See table 1	
MMP12	-1.42	5.07E-14	See table 1	
CCL19	-1.24	2.94E-14	Involved in T and B cell migration to secondary lymphoid organs.	
TNFSF13B	-0.94	1.03E-20	B cell activating factor. Important in B cell proliferation.	
THBS4	-0.93	7.59E-08	Adhesive glycoprotein in cell-to-matrix interactions.	
FGF19	-0.93	1.63E-02	Regulates bile acid synthesis.	
GGH	-0.91	9.66E-18	Key enzyme in intracellular folate homeostasis.	
TNFRSF8	-0.91	1.67E-16	See table 1	
TNFRSF4	-0.91	3.98E-19	OX40 receptor. Combines with OX40 ligand to prolong T cell survival, develop memory T cells, and polarise to Th2 cells.	
CCDC80	-0.9	1.29E-14	Promotes cell adhesion and ECM assembly.	
SIGLEC6	-0.86	2.87E-21	Glycan-binding cell-surface protein highly expressed on mast cells. Inhibits mast cell activation after engagement with specific ligands.	
TNFRSF9	-0.85	9.89E-14	Cell surface protein that stimulates T and B cells, and dendritic cells.	
CD83	-0.84	4.03E-13	Stabilises MHC II.	
IFNG	-0.84	6.50E-03	Interferon gamma. Activates macrophages and MHC class II expression.	
CLEC4C	-0.81	5.93E-06	Cell surface receptor on dendritic cells involved in antigen capturing.	
CCL18	-0.81	2.03E-08	Induces T cell, B cell, and dendritic cell chemotaxis.	
CXCL10	-0.79	3.74E-09	Induces T cell, macrophage, and dendritic cell chemotaxis.	
CCL17	-0.77	4.81E-11	See table 1	
PDCD1	-0.77	2.35E-21	Cell surface receptor on T and B cells that suppresses T cell activity.	
CCL26	-0.75	4.31E-06	See table 1	
CCN3	-0.74	5.80E-10	Binds to integrin and involved ECM structure and function.	

Figures



Graphical abstract





Figure 1 – Schematic of the MAPLE study design and sampling

Participants entered the study at either visit 1 (pre-mepolizumab) or visit 2 (at least 12 weeks postmepolizumab initiation). At visit 2 all participants were randomised to either prednisolone or placebo treatment for 2 weeks, followed by a 4-week washout, and at visit 4 crossed over to receive the opposite treatment for 2 weeks. At visits 1, 3 and 5 (red circle) participants had blood, induced sputum, and nasal scrape sampling. At visits 2 and 4 (blue circle) participants had blood and induced sputum sampling. Blood sampling consisted of EDTA and SST blood tubes.



Figure 2 – Summary of prednisolone effects on proteins measured by Olink® in sputum

A) volcano plot of differentially expressed proteins by prednisolone in sputum. An absolute log2 fold >0.5 (vertical line) and FDR <0.05 (horizonal line) were considered significant. Blue, downregulated by prednisolone; red, upregulated by prednisolone; black, non-significant. B,C) Top 15 most overrepresented Gene Ontology (GO) biological processes significantly downregulated (B) or (C) upregulated by prednisolone in sputum. Colour denotes adjusted p value (FDR<0.05). D) heatmap showing individual change in NPX (n=16 participants) after prednisolone and placebo in the 40 most significantly downregulated sputum proteins from the linear mixed effects model. Participants and proteins underwent unsupervised clustering. Top row denotes treatment received, either placebo (blue) or prednisolone (red). Other rows: red denotes increased protein expression, blue reduced expression.





Matrix of Pearson correlation coefficients between clinical data and change in protein expression for biologically important sputum proteins after prednisolone. Only significant positive (blue) or negative (red) correlations are displayed (p<0.05). Key: feno_pre_treat, FeNO at baseline; delta_feno, change in FeNO after prednisolone; delta fev1, change in FEV₁ after prednisolone; BMI, body mass index at baseline; sp_eos_pc_pre_treatment, sputum eosinophil count at baseline



Figure 4 - Summary of prednisolone effects on proteins measured by Olink[®] in plasma

A) volcano plot of differentially expressed proteins by prednisolone in plasma. An absolute log2 fold >0.5 (vertical line) and FDR <0.05 (horizonal line) were considered significant. Blue, downregulated by prednisolone; red, upregulated by prednisolone; black, non-significant. B,C) Top 15 most overrepresented Gene Ontology (GO) biological processes significantly downregulated (B) or (C) upregulated by prednisolone in plasma. Colour denotes adjusted p value (FDR<0.05). D) heatmap showing individual change in NPX (n=16 participants) after prednisolone and placebo in the 40 most significantly downregulated plasma proteins from the linear mixed effects model. Participants and proteins underwent unsupervised clustering. Top row denotes treatment received, either placebo (blue) or prednisolone (red). Other rows: red denotes increased protein expression, blue reduced expression.



Figure 5 – Differentially expressed nasal genes after mepolizumab

A) volcano plot of differentially expressed genes by mepolizumab in nasal tissue. An absolute log2 fold >0.5 (vertical line) and FDR <0.1 (horizonal line) were considered significant. Blue, downregulated by prednisolone; red, upregulated by prednisolone; black, non-significant. B,C) Top 15 most overrepresented Gene Ontology (GO) biological processes significantly downregulated (B) or (C) upregulated by mepolizumab in nasal tissue. Colour denotes adjusted p value (FDR<0.05).





Figure 6 - Epithelial effects of oral corticosteroids in stable asthma on mepolizumab treatment

Eotaxins (CCL24 and CCL26), CCL17 (TARC) and CCL22 are released by the airway epithelium and dendritic cells in response to IL-4 and TSLP. These chemokines have an important role in stimulating Th2/Tc2 cell and mast cell recruitment via CCR3 and CCR4 receptors. The resultant release of IL-4, IL-5, and IL-13 perpetuates Th2 cell differentiation, stimulates B cell maturation and production of IgE. IL-4 also acts in concert with eotaxins, VCAM, ICAM1, E-selectin, and TIE1 to recruit eosinophils, which are produced in the bone marrow after IL-5 stimulation, to the airway epithelium. Mepolizumab blocks IL-5, thereby reducing the production of eosinophils in the bone marrow. Oral corticosteroids have wider effects than mepolizumab, reducing IL-4, IL-13, eotaxins, CCL17, CCL22 and mast cell activity, and increasing IL-10 activity which inhibits Th2 cell production. CCL, C-C Motif Chemokine Ligand; C-C chemokine receptor, CCR; GM-CSF, Granulocyte-Macrophage Colony-Stimulating Factor; Interleukin, IL; ICAM, Intercellular Adhesion Molecule 1; Thymic Stromal Lymphopoietin, TSLP; VCAM, Vascular Cell Adhesion protein.

Supplementary material















medRxiv preprint doi: https://doi.org/10.1101/2024.02.14.24302812; this version posted February 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

Supplementary figure 1 – The effect of prednisolone on 15 selected proteins in sputum (ELISA)

Summary of the 15 proteins tested by ELISA in sputum samples. This box and whiskers plot shows concentration versus treatment (green, before mepolizumab; light blue, before placebo; dark blue, after placebo; light red, before prednisolone; dark red, after prednisolone). The p value from before to after mepolizumab was determined using paired t-tests, and between prednisolone versus placebo using linear mixed effects modelling. No proteins were significantly regulated by mepolizumab. Prednisolone significantly decreased EDN, and significantly increased IL1Ra.



Supplementary figure 2 – Heatmap showing effect of prednisolone and placebo on nasal transcriptome

Heatmap showing post treatment gene expression (n=6 participants) after prednisolone and placebo in the 31 significantly differentially expressed genes. Participants and genes underwent unsupervised clustering. Top row denotes treatment received, either placebo (blue) or prednisolone (red). Other rows: red denotes high gene expression, blue low expression.



Supplementary figure 3 – Pathways analysis of upregulated Olink[®] sputum proteins after mepolizumab

Top 10 most over-represented Gene Ontology (GO) biological processes for sputum proteins with a trend for upregulation by mepolizumab (FDR<0.15, abs log2fold >0.5). Colour denotes adjusted p value of pathway analysis (FDR<0.05).





Supplementary figure 4 – Pathways analysis of downregulated Olink® plasma proteins after mepolizumab

Top 10 most over-represented Reactome processes for plasma proteins with a trend for downregulation by mepolizumab (FDR<0.15, abs log2fold >0.2). Colour denotes adjusted p value of pathway analysis (FDR<0.05).

Supplementary table 1 – Baseline demographics of patients who had plasma and sputum at all visits in the crossover trial compared with all patients randomised

	Plasma patients	Sputum patients	All randomised
	(N-25)	(N=1C)	patients
Condor	(N=25)	(N=16)	(N=Z7)
Gender	0 (22 0%)	C (27 F0()	0 (22 20()
Female	8 (32.0%)	6 (37.5%)	9 (33.3%)
Male	17 (68.0%)	10 (62.5%)	18 (66.7%)
Age Study Entry			1
Mean (SD)	56.4 (12.3)	60.5 (8.46)	56.9 (12.1)
Median [Min, Max]	58.0 [22.0, 74.0]	62.0 [47.0, 74.0]	58.0 [22.0, 74.0]
Ethnicity	I	1	1
African	1 (4.0%)	1 (6.3%)	1 (3.7%)
Caucasian	24 (96.0%)	15 (93.8%)	26 (96.3%)
Smoking Status			
Ex-smoker	9 (36.0%)	7 (43.8%)	10 (37.0%)
Never smoker	16 (64.0%)	9 (56.3%)	17 (63.0%)
Pack Years			
Mean (SD)	4.26 (9.47)	5.53 (11.4)	4.13 (9.14)
Median [Min, Max]	0 [0, 45.0]	0 [0, 45.0]	0 [0, 45.0]
Age Asthma Diagnosis		·	·
Mean (SD)	31.9 (22.2)	39.3 (21.1)	31.7 (22.1)
Median [Min, Max]	34.0 [0, 66.0]	43.5 [10.0, 66.0]	34.0 [0, 66.0]
BMI_v1		·	·
Mean (SD)	31.4 (5.38)	32.3 (4.81)	31.5 (5.19)
Median [Min, Max]	31.9 [16.8, 40.5]	32.2 [23.8, 40.5]	31.9 [16.8, 40.5]
Missing	1 (4.0%)	1 (6.3%)	1 (3.7%)
Exacerbations Pre Mepo		·	·
Mean (SD)	0.400 (1.26)	0.188 (0.544)	0.370 (1.21)
Median [Min, Max]	0 [0, 6.00]	0 [0, 2.00]	0 [0, 6.00]
Exacerbations requiring ITU/HD	U		
Mean (SD)	0.160 (0.473)	0.125 (0.342)	0.148 (0.456)
Median [Min, Max]	0 [0, 2.00]	0 [0, 1.00]	0 [0, 2.00]
Allergic Rhinitis			
No	21 (84.0%)	14 (87.5%)	22 (81.5%)
Yes	4 (16.0%)	2 (12.5%)	5 (18.5%)
Perenial Rhinitis	I		
No	11 (44.0%)	7 (43.8%)	13 (48.1%)
Yes	14 (56.0%)	9 (56.3%)	14 (51.9%)
Nasal Polyps	1	1	1
No	17 (68.0%)	9 (56.3%)	18 (66.7%)
Yes	8 (32.0%)	7 (43.8%)	9 (33.3%)

Eczema							
No	19 (76.0%)	14 (87.5%)	20 (74.1%)				
Yes	6 (24.0%)	2 (12.5%)	7 (25.9%)				
Depression/Anxiety							
No	20 (80.0%)	12 (75.0%)	22 (81.5%)				
Yes	5 (20.0%)	4 (25.0%)	5 (18.5%)				
Bronchiectasis							
No	23 (92.0%)	14 (87.5%)	24 (88.9%)				
Yes	2 (8.0%)	2 (12.5%)	3 (11.1%)				
Reflux			·				
No	18 (72.0%)	12 (75.0%)	20 (74.1%)				
Yes	7 (28.0%)	4 (25.0%)	7 (25.9%)				
ICS Dose							
Mean (SD)	2020 (300)	2030 (379)	2010 (288)				
Median [Min, Max]	2000 [1000, 3000]	2000 [1000, 3000]	2000 [1000, 3000]				
LABA			·				
Yes	25 (100%)	16 (100%)	27 (100%)				
LTRA			·				
No	9 (36.0%)	5 (31.3%)	9 (33.3%)				
Yes	16 (64.0%)	11 (68.8%)	18 (66.7%)				
LAMA			·				
No	5 (20.0%)	3 (18.8%)	6 (22.2%)				
Yes	20 (80.0%)	13 (81.3%)	21 (77.8%)				
Nebuliser			·				
No	22 (88.0%)	15 (93.8%)	24 (88.9%)				
Yes	3 (12.0%)	1 (6.3%)	3 (11.1%)				
Long term antibiotic							
No	22 (88.0%)	13 (81.3%)	23 (85.2%)				
Yes	3 (12.0%)	3 (18.8%)	4 (14.8%)				

Supplementary table 2 – Clinical measures at randomisation visit (V2) of patients who had plasma and sputum at all visits in the crossover trial compared with all patients randomised

	Plasma patients	Sputum patients	All randomised patients
	(N=25)	(N=16)	(N=27)
ACQ5 Score			
Ν	25	16	27
Mean [SD]	1.09 [1.05]	1.21 [1.14]	1.16 [1.17]
Median [Q1, Q3]	0.600 [0.200, 1.80]	0.600 [0.500, 2.05]	0.600 [0.200, 1.90]
Median [Min, Max]	0.600 [0, 3.60]	0.600 [0, 3.60]	0.600 [0, 4.00]

mAQLQ Score			
Ν	25	16	27
Mean [SD]	5.41 [1.38]	5.41 [1.45]	5.35 [1.48]
Median [Q1, Q3]	5.73 [4.33, 6.53]	5.67 [4.25, 6.63]	5.73 [4.17, 6.57]
Median [Min, Max]	5.73 [2.67, 7.00]	5.67 [2.67, 7.00]	5.73 [2.27, 7.00]
SGRQ Total			
Ν	25	16	27
Mean [SD]	29.8 [20.3]	30.8 [22.0]	30.3 [21.9]
Median [Q1, Q3]	30.7 [14.7, 46.2]	33.1 [15.0, 46.3]	30.7 [13.9, 46.3]
Median [Min, Max]	30.7 [0.850, 69.6]	33.1 [0.850, 69.6]	30.7 [0, 70.6]
VAS Overall			
Ν	23	16	25
Mean [SD]	2.47 [2.28]	2.49 [2.34]	2.47 [2.31]
Median [Q1, Q3]	2.00 [0.450, 4.25]	2.00 [0.475, 4.00]	2.00 [0.300, 4.50]
Median [Min, Max]	2.00 [0, 8.00]	2.00 [0, 8.00]	2.00 [0, 8.00]
Missing	2 (8.0%)		2 (7.4%)
VAS SOB			·
Ν	23	16	25
Mean [SD]	2.58 [2.47]	2.68 [2.58]	2.65 [2.58]
Median [Q1, Q3]	2.00 [0.400, 5.00]	2.00 [0.500, 5.00]	2.00 [0.200, 5.00]
Median [Min, Max]	2.00 [0, 8.00]	2.00 [0, 8.00]	2.00 [0, 8.00]
Missing	2 (8.0%)		2 (7.4%)
VAS Cough			
Ν	23	16	25
Mean [SD]	2.29 [2.43]	2.54 [2.68]	2.39 [2.56]
Median [Q1, Q3]	1.00 [0.100, 4.25]	1.20 [0.150, 5.00]	1.00 [0, 4.50]
Median [Min, Max]	1.00 [0, 7.60]	1.20 [0, 7.60]	1.00 [0, 7.60]
Missing	2 (8.0%)		2 (7.4%)
Airway oscillometry R5			
Ν	25	16	27
Mean [SD]	4.01 [1.72]	3.78 [1.58]	4.04 [1.73]
Median [Q1, Q3]	3.53 [2.84, 4.85]	3.47 [2.81, 4.71]	3.53 [2.71, 4.94]
Median [Min, Max]	3.53 [1.48, 7.78]	3.47 [1.48, 7.64]	3.53 [1.48, 7.78]
Airway oscillometry R5-20			
Ν	25	16	27
Mean [SD]	1.00 [1.09]	0.963 [1.06]	1.02 [1.11]
Median [Q1, Q3]	0.670 [0.304, 1.36]	0.720 [0.335, 1.34]	0.670 [0.282, 1.62]
Median [Min, Max]	0.670 [-0.460, 3.60]	0.720 [-0.460, 3.60]	0.670 [-0.460, 3.60]
AX	0.001		
N	25	16	27
Mean [SD]	17.5 [18.0]	19.2 [19.5]	18.3 [18.8]

Median [Q1, Q3]	7.92 [4.88, 30.8]	9.34 [4.70, 32.8]	7.92 [4.89, 31.3]
Median [Min, Max]	7.92 [0.730, 57.5]	9.34 [0.730, 57.5]	7.92 [0.730, 57.5]
Airway oscillometry X5			
Ν	25	16	27
Mean [SD]	-1.24 [2.48]	-1.08 [2.86]	-1.39 [2.50]
Median [Q1, Q3]	-0.870 [-2.57, - 0.480]	-0.840 [-2.59, -0.475]	-1.11 [-2.61, -0.535]
Median [Min, Max]	-0.870 [-6.14, 7.71]	-0.840 [-6.14, 7.71]	-1.11 [-6.14, 7.71]
FEV1 (% predicted)			
Ν	25	16	27
Mean [SD]	77.9 [18.9]	81.2 [20.7]	77.0 [20.2]
Median [Q1, Q3]	79.0 [67.0, 88.0]	85.0 [70.8, 99.3]	79.0 [66.0, 91.5]
Median [Min, Max]	79.0 [32.0, 107]	85.0 [32.0, 107]	79.0 [32.0, 107]
FVC (% predicted)			
Ν	25	16	27
Mean [SD]	92.9 [15.6]	96.5 [14.8]	91.8 [16.6]
Median [Q1, Q3]	95.0 [83.0, 104]	101 [8.38, 108]	9.50 [8.15, 104]
Median [Min, Max]	95.0 [52.0, 118]	101 [70.7, 118]	95.0 [52.0, 118]
FEV1/FVC ratio			
Ν	25	16	27
Mean [SD]	0.662 [0.122]	0.661 [0.121]	0.659 [0.122]
Median [Q1, Q3]	0.670 [0.650, 0.720]	0.670 [0.650, 0.703]	0.670 [0.650, 0.730]
Median [Min, Max]	0.670 [0.280, 0.830]	0.670 [0.280, 0.830]	0.670 [0.280, 0.830]
FEF (% predicted)			
Ν	18	9	18
Mean [SD]	0.531 [0.245]	0.607 [0.268]	0.531 [0.245]
Median [Q1, Q3]	0.510 [0.383, 0.603]	0.520 [0.490, 0.610]	0.510 [0.383, 0.603]
Median [Min, Max]	0.510 [0.130, 1.17]	0.520 [0.320, 1.17]	0.510 [0.130, 1.17]
Missing	7 (28.0%)	7 (43.8%)	9 (33.3%)
PEF (L/min)			
Ν	25	16	27
Mean [SD]	457 [141]	451 [143]	446 [145]
Median [Q1, Q3]	425 [343, 550]	435 [337, 572]	424 [341, 537]
Median [Min, Max]	425 [224, 805]	435 [224, 705]	424 [202, 805]
FeNO (ppb)			
Ν	25	16	27
Mean [SD]	47.2 [32.6]	49.5 [34.0]	44.9 [32.4]
Median [Q1, Q3]	37.0 [26.0, 61.0]	40.0 [26.3, 61.5]	37.0 [23.0, 59.0]
Median [Min, Max]	37.0 [3.00, 134]	40.0 [3.00, 134]	37.0 [3.00, 134]

Blood WCC			
Ν	25	16	27
Mean [SD]	6.65 [1.48]	6.96 [1.53]	6.51 [1.52]
Median [Q1, Q3]	6.20 [5.70, 7.82]	6.20 [5.85, 8.04]	6.00 [5.55, 7.46]
Median [Min, Max]	6.20 [4.00, 10.2]	6.20 [5.10, 10.2]	6.00 [4.00, 10.2]
Blood Neutrophils			
Ν	25	16	27
Mean [SD]	3.91 [1.10]	4.01 [1.16]	3.82 [1.11]
Median [Q1, Q3]	3.70 [3.20, 4.40]	3.75 [3.38, 4.18]	3.70 [3.02, 4.25]
Median [Min, Max]	3.70 [2.57, 6.51]	3.75 [2.60, 6.51]	3.70 [2.45, 6.51]
Blood Eosinophils			
Ν	25	16	27
Mean [SD]	0.0784 [0.0657]	0.0856 [0.0756]	0.0763 [0.0637]
Median [Q1, Q3]	0.0600 [0.0400, 0.0900]	0.0600 [0.0400, 0.0950]	0.0600 [0.0400, 0.0900]
Median [Min, Max]	0.0600 [0.0200, 0.320]	0.0600 [0.0200, 0.320]	0.0600 [0.0200, 0.320]
Sputum Macrophages (% t	otal)		
Ν	20	15	22
Mean [SD]	24.2 [23.5]	22.5 [21.1]	28.8 [28.0]
Median [Q1, Q3]	16.8 [8.16, 28.7]	15.8 [9.45, 23.4]	19.5 [9.08, 44.1]
Median [Min, Max]	16.8 [1.10, 81.1]	15.8 [1.10, 70.0]	19.5 [1.10, 99.2]
Missing	5 (20.0%)	1 (6.3%)	5 (18.5%)
Sputum Neutrophils (% tot	tal)		
Ν	20	15	22
Mean [SD]	64.3 [28.6]	68.3 [25.6]	60.6 [30.6]
Median [Q1, Q3]	72.4 [46.9, 84.4]	75.8 [58.2, 86.1]	69.8 [37.1, 82.6]
Median [Min, Max]	72.4 [12.8, 98.8]	75.8 [17.5, 97.0]	69.8 [0.500, 98.8]
Missing	5 (20.0%)	1 (6.3%)	5 (18.5%)
Sputum Eosinophils (% tot	al)	1	r
Ν	20	15	22
Mean [SD]	6.90 [16.6]	6.88 [18.6]	6.29 [15.9]
Median [Q1, Q3]	1.04 [0, 5.92]	0.730 [0.100, 4.88]	0.645 [0, 5.31]
Median [Min, Max]	1.04 [0, 73.5]	0.730 [0, 73.5]	0.645 [0, 73.5]
Missing	5 (20.0%)	1 (6.3%)	5 (18.5%)
Sputum Lymphocytes (% to	otal)	1	Γ
Ν	20	15	22
Mean [SD]	0.370 [0.687]	0.476 [0.767]	0.390 [0.669]
Median [Q1, Q3]	0 [0, 0.275]	0 [0, 0.515]	0 [0, 0.325]
Median [Min, Max]	0 [0, 2.17]	0 [0, 2.17]	0 [0, 2.17]
Missing	5 (20.0%)	1 (6.3%)	5 (18.5%)

Supplementary table 3 – Proteins significantly downregulated by prednisolone versus placebo in sputum (Olink®)

International Post of the second		Assay	UniProt	Log2fold change	Adjusted p
1 14 P0312 -3.3 4.81E-03 2 SERPINA9 Q86WD7 -3.18 9.79E-06 3 CCL24 000175 -2.6 2.47E-04 4 MMP1 P03956 -2.6 1.44E-03 5 HLA-DRA P01903 -2.46 1.88E-04 6 TIE1 P35590 -2.44 3.70E-04 7 CCL26 Q9Y258 -2.43 5.02E-03 8 CCL27 000626 -2.43 2.79E-02 9 CCL17 Q92583 -2.37 6.68E-03 10 GDNF P39905 -2.29 3.96E-03 11 NCAM1 P13591 -2.18 6.60E-04 12 TIMD4 Q96H15 -2.16 8.56E-05 13 CCL3 Q99616 -2.15 6.92E-03 14 NCAN 014594 -2.11 1.99E-04 15 MCAM P43121 -2.09 1.93E-04 16	1	11.4	DOE112	2 27	value
2 SERFINARY CROWD/ -5.18 5.79E-06 3 CCL24 000175 -2.6 2.47E-04 4 MMP1 P03956 -2.6 1.44E-03 5 HLA-DRA P01903 -2.46 1.88E-04 6 TIE1 P35590 -2.44 3.70E-04 7 CCL26 Q9Y258 -2.43 5.02E-03 8 CCL27 Q92583 -2.37 6.68E-03 10 GDNF P39905 -2.29 3.96E-03 11 NCAM1 P13591 -2.18 6.60E-04 12 TIMD4 Q96H15 -2.16 8.56E-05 13 CCL13 Q99616 -2.15 6.92E-03 14 NCAN O14594 -2.11 1.99E-04 15 MCAM P43121 -2.09 1.93E-04 16 SELE P16581 -2.07 4.36E-03 17 DOK2 O60496 -2.03 1.40E-03 20 </td <td>1</td> <td></td> <td></td> <td>-3.37</td> <td>4.81E-03</td>	1			-3.37	4.81E-03
3 CCL24 O00175 -2.6 2.47E-04 4 MMP1 P03956 -2.6 1.44E-03 5 HLA-DRA P01903 -2.46 1.88E-04 6 TIE1 P35590 -2.44 3.70E-04 7 CCL26 Q9Y258 -2.43 5.02E-03 8 CCL27 Q92583 -2.37 6.68E-03 10 GDNF P39905 -2.29 3.96E-03 11 NCAM1 P13591 -2.18 6.60E-04 12 TIMD4 Q96H15 -2.16 8.56E-05 13 CCL13 Q99616 -2.15 6.92E-03 14 NCAN O14594 -2.11 1.99E-04 15 MCAM P43121 -2.09 1.93E-04 16 SELE P16581 -2.07 4.36E-03 18 IL5 P05113 -2.06 2.89E-04 19 GP1BA P07359 -2.04 2.65E-04 20	2	SERPINAS	Q86WD7	-3.18	9.79E-06
4 MMP1 P03956 -2.6 1.44E-03 5 HLA-DRA P01903 -2.46 1.88E-04 6 TIE1 P35590 -2.44 3.70E-04 7 CCL26 Q9Y258 -2.43 5.02E-03 8 CCL27 Q00626 -2.43 2.79E-02 9 CCL17 Q92583 -2.29 3.96E-03 10 GDNF P39905 -2.29 3.96E-03 11 NCAM1 P13591 -2.18 6.60E-04 12 TIMD4 Q96H15 -2.16 8.56E-05 13 CCL13 Q99616 -2.15 6.92E-03 14 NCAN O14594 -2.11 1.99E-04 15 MCAM P43121 -2.09 1.93E-04 16 SELE P16581 -2.07 4.36E-03 18 IL5 P05113 -2.06 2.89E-04 19 GP1BA P07359 -2.04 2.65E-04 20 VCAM1 P19320 -2.03 1.40E-03 21 CPA2	3		000175	-2.6	2.4/E-04
S HLA-DRA P01903 -2.46 1.88E-04 6 TIE1 P35590 -2.44 3.70E-04 7 CCL26 Q9Y258 -2.43 5.02E-03 8 CCL22 000626 -2.43 2.79E-02 9 CCL17 Q92583 -2.37 6.68E-03 10 GDNF P39905 -2.29 3.96E-03 11 NCAM1 P13591 -2.18 6.60E-04 12 TIMD4 Q96H15 -2.16 8.56E-05 13 CCL13 Q99616 -2.15 6.92E-03 14 NCAN O14594 -2.11 1.99E-04 15 MCAM P43121 -2.09 1.93E-04 16 SELE P16581 -2.07 4.36E-03 18 IL5 P05113 -2.06 2.89E-04 19 GP1BA P07359 -2.04 2.65E-04 20 VCAM1 P19320 -2.03 1.40E-03 21 <	4		P03956	-2.6	1.44E-03
6 TIE1 P35590 -2.44 3.70E-04 7 CCL26 Q9Y258 -2.43 5.02E-03 8 CCL22 000626 -2.43 2.79E-02 9 CCL17 Q92583 -2.37 6.68E-03 10 GDNF P39905 -2.29 3.96E-03 11 NCAM1 P13591 -2.18 6.60E-04 12 TIMD4 Q96H15 -2.16 8.56E-05 13 CCL13 Q99616 -2.15 6.92E-03 14 NCAN O14594 -2.11 1.99E-04 15 MCAM P43121 -2.09 1.93E-04 16 SELE P16581 -2.07 4.36E-03 18 IL5 P05113 -2.06 2.89E-04 19 GP1BA P07359 -2.04 2.65E-04 20 VCAM1 P19320 -2.03 1.40E-03 21 CPA2 P48052 -2 1.47E-02 22	5	HLA-DRA	P01903	-2.46	1.88E-04
7 CCL26 C9Y258 -2.43 5.02E-03 8 CCL22 O00626 -2.43 2.79E-02 9 CCL17 Q92583 -2.37 6.68E-03 10 GDNF P39905 -2.29 3.96E-03 11 NCAM1 P13591 -2.18 6.60E-04 12 TIMD4 Q96H15 -2.16 8.56E-05 13 CCL13 Q99616 -2.15 6.92E-03 14 NCAN O14594 -2.11 1.99E-04 15 MCAM P43121 -2.09 1.93E-04 16 SELE P16581 -2.07 4.36E-03 18 IL5 P05113 -2.06 2.89E-04 19 GP1BA P07359 -2.04 2.65E-04 20 VCAM1 P19320 -2.03 1.40E-03 21 CPA2 P48052 -2 1.47E-02 22 ARSB P15848 -1.97 6.09E-03 24	6	TIE1	P35590	-2.44	3.70E-04
8 CCL22 O00626 -2.43 2.79E-02 9 CCL17 Q92583 -2.37 6.68E-03 10 GDNF P39905 -2.29 3.96E-03 11 NCAM1 P13591 -2.18 6.60E-04 12 TIMD4 Q96H15 -2.16 8.56E-05 13 CCL13 Q99616 -2.15 6.92E-03 14 NCAN O14594 -2.11 1.99E-04 15 MCAM P43121 -2.09 1.93E-04 16 SELE P16581 -2.07 3.74E-04 17 DOK2 O60496 -2.07 4.36E-03 18 IL5 P05113 -2.06 2.89E-04 19 GP1BA P07359 -2.04 2.65E-04 20 VCAM1 P19320 -2.03 1.40E-03 21 CPA2 P48052 -2 1.47E-02 22 ARSB P15848 -1.97 6.09E-03 24	7	CCL26	Q9Y258	-2.43	5.02E-03
9 CCL17 Q92583 -2.37 6.68E-03 10 GDNF P39905 -2.29 3.96E-03 11 NCAM1 P13591 -2.18 6.60E-04 12 TIMD4 Q96H15 -2.16 8.56E-05 13 CCL13 Q99616 -2.15 6.92E-03 14 NCAN O14594 -2.11 1.99E-04 15 MCAM P43121 -2.09 1.93E-04 16 SELE P16581 -2.07 3.74E-04 17 DOK2 060496 -2.07 4.36E-03 18 IL5 P05113 -2.06 2.89E-04 19 GP1BA P07359 -2.04 2.65E-04 20 VCAM1 P19320 -2.03 1.40E-03 21 CPA2 P48052 -2 1.47E-02 22 ARSB P15848 -1.97 2.63E-03 23 MMP12 P39900 -1.97 6.09E-03 24	8	CCL22	000626	-2.43	2.79E-02
10 GDNF P39905 -2.29 3.96E-03 11 NCAM1 P13591 -2.18 6.60E-04 12 TIMD4 Q96H15 -2.16 8.56E-05 13 CCL13 Q99616 -2.15 6.92E-03 14 NCAN O14594 -2.11 1.99E-04 15 MCAM P43121 -2.09 1.93E-04 16 SELE P16581 -2.07 3.74E-04 17 DOK2 O60496 -2.07 4.36E-03 18 IL5 P05113 -2.06 2.89E-04 19 GP1BA P07359 -2.04 2.65E-04 20 VCAM1 P19320 -2.03 1.40E-03 21 CPA2 P48052 -2 1.47E-02 22 ARSB P15848 -1.97 2.63E-03 23 MMP12 P39900 -1.97 6.09E-03 24 TNFRSF8 P28908 -1.95 5.57E-05 25	9	CCL17	Q92583	-2.37	6.68E-03
11 NCAM1 P13591 -2.18 6.60E-04 12 TIMD4 Q96H15 -2.16 8.56E-05 13 CCL13 Q99616 -2.15 6.92E-03 14 NCAN O14594 -2.11 1.99E-04 15 MCAM P43121 -2.09 1.93E-04 16 SELE P16581 -2.07 4.36E-03 18 IL5 P05113 -2.06 2.89E-04 19 GP1BA P07359 -2.04 2.65E-04 20 VCAM1 P19320 -2.03 1.40E-03 21 CPA2 P48052 -2 1.47E-02 22 ARSB P15848 -1.97 2.63E-03 23 MMP12 P39900 -1.97 6.09E-03 24 TNFRSF8 P28908 -1.95 5.57E-05 25 SPP1 P10451 -1.94 8.87E-04 26 FCER2 P06734 -1.9 5.89E-04 27 OGN P20774 -1.88 1.04E-03 29 LEP	10	GDNF	P39905	-2.29	3.96E-03
12 TIMD4 Q96H15 -2.16 8.56E-05 13 CCL13 Q99616 -2.15 6.92E-03 14 NCAN O14594 -2.11 1.99E-04 15 MCAM P43121 -2.09 1.93E-04 16 SELE P16581 -2.07 3.74E-04 17 DOK2 O60496 -2.07 4.36E-03 18 IL5 P05113 -2.06 2.89E-04 19 GP1BA P07359 -2.04 2.65E-04 20 VCAM1 P19320 -2.03 1.40E-03 21 CPA2 P48052 -2 1.47E-02 22 ARSB P15848 -1.97 2.63E-03 23 MMP12 P39900 -1.97 6.09E-03 24 TNFRSF8 P28908 -1.95 5.57E-05 25 SPP1 P10451 -1.94 8.87E-04 26 FCER2 P06734 -1.9 5.89E-04 27 OGN P20774 -1.88 9.49E-05 28 THBS4	11	NCAM1	P13591	-2.18	6.60E-04
13 CCL13 Q99616 -2.15 6.92E-03 14 NCAN O14594 -2.11 1.99E-04 15 MCAM P43121 -2.09 1.93E-04 16 SELE P16581 -2.07 3.74E-04 17 DOK2 O60496 -2.07 4.36E-03 18 IL5 P05113 -2.06 2.89E-04 19 GP1BA P07359 -2.04 2.65E-04 20 VCAM1 P19320 -2.03 1.40E-03 21 CPA2 P48052 -2 1.47E-02 22 ARSB P15848 -1.97 2.63E-03 23 MMP12 P39900 -1.97 6.09E-03 24 TNFRSF8 P28908 -1.95 5.57E-05 25 SPP1 P10451 -1.94 8.87E-04 26 FCER2 P06734 -1.9 5.89E-04 27 OGN P20774 -1.88 9.49E-05 28 THBS4 P3543 -1.82 5.21E-03 32 TNXB	12	TIMD4	Q96H15	-2.16	8.56E-05
14 NCAN 014594 -2.11 1.99E-04 15 MCAM P43121 -2.09 1.93E-04 16 SELE P16581 -2.07 3.74E-04 17 DOK2 O60496 -2.07 4.36E-03 18 IL5 P05113 -2.06 2.89E-04 19 GP1BA P07359 -2.04 2.65E-04 20 VCAM1 P19320 -2.03 1.40E-03 21 CPA2 P48052 -2 1.47E-02 22 ARSB P15848 -1.97 2.63E-03 23 MMP12 P39900 -1.97 6.09E-03 24 TNFRSF8 P28908 -1.95 5.57E-05 25 SPP1 P10451 -1.94 8.87E-04 26 FCER2 P06734 -1.9 5.89E-04 27 OGN P20774 -1.88 1.04E-03 29 LEP P41159 -1.87 7.13E-04 30 FABP1 P07148 -1.83 1.82E-02 31 CPA1	13	CCL13	Q99616	-2.15	6.92E-03
15 MCAM P43121 -2.09 1.93E-04 16 SELE P16581 -2.07 3.74E-04 17 DOK2 O60496 -2.07 4.36E-03 18 IL5 P05113 -2.06 2.89E-04 19 GP1BA P07359 -2.04 2.65E-04 20 VCAM1 P19320 -2.03 1.40E-03 21 CPA2 P48052 -2 1.47E-02 22 ARSB P15848 -1.97 2.63E-03 23 MMP12 P39900 -1.97 6.09E-03 24 TNFRSF8 P28908 -1.95 5.57E-05 25 SPP1 P10451 -1.94 8.87E-04 26 FCER2 P06734 -1.9 5.89E-04 27 OGN P20774 -1.88 1.04E-03 29 LEP P41159 -1.87 7.13E-04 30 FABP1 P07148 -1.82 5.21E-03 31	14	NCAN	014594	-2.11	1.99E-04
16SELEP16581-2.073.74E-0417DOK2O60496-2.074.36E-0318IL5P05113-2.062.89E-0419GP1BAP07359-2.042.65E-0420VCAM1P19320-2.031.40E-0321CPA2P48052-21.47E-0222ARSBP15848-1.972.63E-0323MMP12P39900-1.976.09E-0324TNFRSF8P28908-1.955.57E-0525SPP1P10451-1.948.87E-0426FCER2P06734-1.95.89E-0427OGNP20774-1.889.49E-0528THBS4P35443-1.831.82E-0230FABP1P07148-1.831.82E-0231CPA1P15085-1.786.98E-0433LAP3P2838-1.744.13E-0234TCL1AP56279-1.734.80E-0335KRT18P05783-1.725.54E-0336TREM2Q9NZC2-1.74.96E-03	15	MCAM	P43121	-2.09	1.93E-04
17DOK2O60496-2.074.36E-0318IL5P05113-2.062.89E-0419GP1BAP07359-2.042.65E-0420VCAM1P19320-2.031.40E-0321CPA2P48052-21.47E-0222ARSBP15848-1.972.63E-0323MMP12P39900-1.976.09E-0324TNFRSF8P28908-1.955.57E-0525SPP1P10451-1.948.87E-0426FCER2P06734-1.95.89E-0427OGNP20774-1.889.49E-0528THBS4P35443-1.831.04E-0329LEPP41159-1.877.13E-0430FABP1P07148-1.831.82E-0231CPA1P15085-1.825.21E-0332TNXBP22105-1.786.98E-0433LAP3P2838-1.744.13E-0234TCL1AP56279-1.734.80E-0335KRT18P05783-1.725.54E-0336TREM2Q9NZC2-1.74.96E-03	16	SELE	P16581	-2.07	3.74E-04
18 IL5 P05113 -2.06 2.89E-04 19 GP1BA P07359 -2.04 2.65E-04 20 VCAM1 P19320 -2.03 1.40E-03 21 CPA2 P48052 -2 1.47E-02 22 ARSB P15848 -1.97 2.63E-03 23 MMP12 P39900 -1.97 6.09E-03 24 TNFRSF8 P28908 -1.95 5.57E-05 25 SPP1 P10451 -1.94 8.87E-04 26 FCER2 P06734 -1.9 5.89E-04 27 OGN P20774 -1.88 9.49E-05 28 THBS4 P35443 -1.88 1.04E-03 29 LEP P41159 -1.87 7.13E-04 30 FABP1 P07148 -1.83 1.82E-02 31 CPA1 P15085 -1.82 5.21E-03 32 TNXB P22105 -1.78 6.98E-04 33 LAP3 P2838 -1.74 4.13E-02 34 TCL1A	17	DOK2	O60496	-2.07	4.36E-03
19GP1BAP07359-2.042.65E-0420VCAM1P19320-2.031.40E-0321CPA2P48052-21.47E-0222ARSBP15848-1.972.63E-0323MMP12P39900-1.976.09E-0324TNFRSF8P28908-1.955.57E-0525SPP1P10451-1.948.87E-0426FCER2P06734-1.95.89E-0427OGNP20774-1.889.49E-0528THBS4P35443-1.881.04E-0329LEPP41159-1.877.13E-0430FABP1P07148-1.831.82E-0231CPA1P15085-1.825.21E-0332TNXBP22105-1.786.98E-0433LAP3P28838-1.744.13E-0234TCL1AP56279-1.734.80E-0335KRT18P05783-1.725.54E-0336TREM2Q9NZC2-1.74.96E-03	18	IL5	P05113	-2.06	2.89E-04
20 VCAM1 P19320 -2.03 1.40E-03 21 CPA2 P48052 -2 1.47E-02 22 ARSB P15848 -1.97 2.63E-03 23 MMP12 P39900 -1.97 6.09E-03 24 TNFRSF8 P28908 -1.95 5.57E-05 25 SPP1 P10451 -1.94 8.87E-04 26 FCER2 P06734 -1.9 5.89E-04 27 OGN P20774 -1.88 9.49E-05 28 THBS4 P35443 -1.88 1.04E-03 29 LEP P41159 -1.87 7.13E-04 30 FABP1 P07148 -1.83 1.82E-02 31 CPA1 P15085 -1.82 5.21E-03 32 TNXB P22105 -1.78 6.98E-04 33 LAP3 P28838 -1.74 4.13E-02 34 TCL1A P56279 -1.73 4.80E-03 35	19	GP1BA	P07359	-2.04	2.65E-04
21CPA2P48052-21.47E-0222ARSBP15848-1.972.63E-0323MMP12P39900-1.976.09E-0324TNFRSF8P28908-1.955.57E-0525SPP1P10451-1.948.87E-0426FCER2P06734-1.95.89E-0427OGNP20774-1.889.49E-0528THBS4P35443-1.881.04E-0329LEPP41159-1.877.13E-0430FABP1P07148-1.825.21E-0331CPA1P15085-1.825.21E-0332TNXBP22105-1.786.98E-0433LAP3P2838-1.744.13E-0234TCL1AP56279-1.734.80E-0335KRT18P05783-1.725.54E-0336TREM2Q9NZC2-1.74.96E-03	20	VCAM1	P19320	-2.03	1.40E-03
22 ARSB P15848 -1.97 2.63E-03 23 MMP12 P39900 -1.97 6.09E-03 24 TNFRSF8 P28908 -1.95 5.57E-05 25 SPP1 P10451 -1.94 8.87E-04 26 FCER2 P06734 -1.9 5.89E-04 27 OGN P20774 -1.88 9.49E-05 28 THBS4 P35443 -1.88 1.04E-03 29 LEP P41159 -1.87 7.13E-04 30 FABP1 P07148 -1.83 1.82E-02 31 CPA1 P15085 -1.82 5.21E-03 32 TNXB P22105 -1.78 6.98E-04 33 LAP3 P2838 -1.74 4.13E-02 34 TCL1A P56279 -1.73 4.80E-03 35 KRT18 P05783 -1.72 5.54E-03 36 TREM2 Q9NZC2 -1.7 4.96E-03	21	CPA2	P48052	-2	1.47E-02
23MMP12P39900-1.976.09E-0324TNFRSF8P28908-1.955.57E-0525SPP1P10451-1.948.87E-0426FCER2P06734-1.95.89E-0427OGNP20774-1.889.49E-0528THBS4P35443-1.881.04E-0329LEPP41159-1.877.13E-0430FABP1P07148-1.831.82E-0231CPA1P15085-1.825.21E-0332TNXBP22105-1.786.98E-0433LAP3P28838-1.744.13E-0234TCL1AP56279-1.734.80E-0335KRT18P05783-1.725.54E-0336TREM2Q9NZC2-1.74.96E-03	22	ARSB	P15848	-1.97	2.63E-03
24TNFRSF8P28908-1.955.57E-0525SPP1P10451-1.948.87E-0426FCER2P06734-1.95.89E-0427OGNP20774-1.889.49E-0528THBS4P35443-1.881.04E-0329LEPP41159-1.877.13E-0430FABP1P07148-1.831.82E-0231CPA1P15085-1.825.21E-0332TNXBP22105-1.786.98E-0433LAP3P28838-1.744.13E-0234TCL1AP56279-1.734.80E-0335KRT18P05783-1.725.54E-0336TREM2Q9NZC2-1.74.96E-03	23	MMP12	P39900	-1.97	6.09E-03
25SPP1P10451-1.948.87E-0426FCER2P06734-1.95.89E-0427OGNP20774-1.889.49E-0528THBS4P35443-1.881.04E-0329LEPP41159-1.877.13E-0430FABP1P07148-1.831.82E-0231CPA1P15085-1.825.21E-0332TNXBP22105-1.786.98E-0433LAP3P28838-1.744.13E-0234TCL1AP56279-1.734.80E-0335KRT18P05783-1.725.54E-0336TREM2Q9NZC2-1.74.96E-03	24	TNFRSF8	P28908	-1.95	5.57E-05
26FCER2P06734-1.95.89E-0427OGNP20774-1.889.49E-0528THBS4P35443-1.881.04E-0329LEPP41159-1.877.13E-0430FABP1P07148-1.831.82E-0231CPA1P15085-1.825.21E-0332TNXBP22105-1.786.98E-0433LAP3P28838-1.744.13E-0234TCL1AP56279-1.734.80E-0335KRT18P05783-1.725.54E-0336TREM2Q9NZC2-1.74.96E-03	25	SPP1	P10451	-1.94	8.87E-04
27OGNP20774-1.889.49E-0528THBS4P35443-1.881.04E-0329LEPP41159-1.877.13E-0430FABP1P07148-1.831.82E-0231CPA1P15085-1.825.21E-0332TNXBP22105-1.786.98E-0433LAP3P28838-1.744.13E-0234TCL1AP56279-1.734.80E-0335KRT18P05783-1.725.54E-0336TREM2Q9NZC2-1.74.96E-03	26	FCER2	P06734	-1.9	5.89E-04
28THBS4P35443-1.881.04E-0329LEPP41159-1.877.13E-0430FABP1P07148-1.831.82E-0231CPA1P15085-1.825.21E-0332TNXBP22105-1.786.98E-0433LAP3P28838-1.744.13E-0234TCL1AP56279-1.734.80E-0335KRT18P05783-1.725.54E-0336TREM2Q9NZC2-1.74.96E-03	27	OGN	P20774	-1.88	9.49E-05
29LEPP41159-1.877.13E-0430FABP1P07148-1.831.82E-0231CPA1P15085-1.825.21E-0332TNXBP22105-1.786.98E-0433LAP3P28838-1.744.13E-0234TCL1AP56279-1.734.80E-0335KRT18P05783-1.725.54E-0336TREM2Q9NZC2-1.74.96E-03	28	THBS4	P35443	-1.88	1.04E-03
30 FABP1 P07148 -1.83 1.82E-02 31 CPA1 P15085 -1.82 5.21E-03 32 TNXB P22105 -1.78 6.98E-04 33 LAP3 P28838 -1.74 4.13E-02 34 TCL1A P56279 -1.73 4.80E-03 35 KRT18 P05783 -1.72 5.54E-03 36 TREM2 Q9NZC2 -1.7 4.96E-03	29	LEP	P41159	-1.87	7.13E-04
31 CPA1 P15085 -1.82 5.21E-03 32 TNXB P22105 -1.78 6.98E-04 33 LAP3 P28838 -1.74 4.13E-02 34 TCL1A P56279 -1.73 4.80E-03 35 KRT18 P05783 -1.72 5.54E-03 36 TREM2 Q9NZC2 -1.7 4.96E-03	30	FABP1	P07148	-1.83	1.82E-02
32 TNXB P22105 -1.78 6.98E-04 33 LAP3 P28838 -1.74 4.13E-02 34 TCL1A P56279 -1.73 4.80E-03 35 KRT18 P05783 -1.72 5.54E-03 36 TREM2 Q9NZC2 -1.7 4.96E-03	31	CPA1	P15085	-1.82	5.21E-03
33 LAP3 P28838 -1.74 4.13E-02 34 TCL1A P56279 -1.73 4.80E-03 35 KRT18 P05783 -1.72 5.54E-03 36 TREM2 Q9NZC2 -1.7 4.96E-03	32	TNXB	P22105	-1.78	6.98E-04
34 TCL1A P56279 -1.73 4.80E-03 35 KRT18 P05783 -1.72 5.54E-03 36 TREM2 Q9NZC2 -1.7 4.96E-03 37 HMOD P07011 4.60 4.705.05	33	LAP3	P28838	-1.74	4.13E-02
35 KRT18 P05783 -1.72 5.54E-03 36 TREM2 Q9NZC2 -1.7 4.96E-03 37 HMADD P07011 4.00 4.705	34	TCL1A	P56279	-1.73	4.80E-03
36 TREM2 Q9NZC2 -1.7 4.96E-03 37 UMADD D07011 4.00 4.705 65	35	KRT18	P05783	-1.72	5.54E-03
	36	TREM2	Q9NZC2	-1.7	4.96E-03
37 UNIUD PU7911 -1.69 1.70E-03	37	UMOD	P07911	-1.69	1.70E-03
38 ANGPTL3 Q9Y5C1 -1.69 3.23E-03	38	ANGPTL3	Q9Y5C1	-1.69	3.23E-03
39 CD69 Q07108 -1.67 6.28F-03	39	CD69	Q07108	-1.67	6.28E-03
40 STC2 076061 -1.65 3.08E-03	40	STC2	076061	-1.65	3.08E-03

41	MB	P02144	-1.63	2.74E-02
42	HAVCR2	Q8TDQ0	-1.61	1.13E-02
43	APEX1	P27695	-1.6	1.94E-02
44	LILRB5	075023	-1.6	2.03E-03
45	DLK1	P80370	-1.6	2.58E-04
46	FOLR3	P41439	-1.6	6.44E-03
47	CR2	P20023	-1.6	7.73E-03
48	CCL23	P55773	-1.59	1.33E-02
49	FBP1	P09467	-1.57	2.12E-02
50	VSTM2L	Q96N03	-1.57	1.98E-02
51	ENO1	P06733	-1.56	2.98E-04
52	ICAM2	P13598	-1.56	5.49E-03
53	ITIH3	Q06033	-1.56	3.19E-02
54	AARSD1	Q9BTE6	-1.55	5.36E-03
55	ICAM5	Q9UMF0	-1.52	2.12E-02
56	FETUB	Q9UGM5	-1.5	4.42E-02
57	LAIR2	Q6ISS4	-1.49	4.46E-05
58	TNFRSF4	P43489	-1.47	5.71E-04
59	GP6	Q9HCN6	-1.47	2.40E-03
60	VWF	P04275	-1.45	4.92E-02
61	PLPBP	O94903	-1.45	4.60E-02
62	CD209	Q9NNX6	-1.44	3.85E-02
63	PROC	P04070	-1.44	4.28E-02
64	APOM	095445	-1.42	1.11E-02
65	CASP3	P42574	-1.41	2.81E-02
66	MEPE	Q9NQ76	-1.4	8.37E-04
67	AOC3	Q16853	-1.4	1.38E-02
68	SIGLEC6	O43699	-1.37	1.18E-02
69	SSC5D	A1L4H1	-1.36	3.58E-04
70	GPA33	Q99795	-1.36	4.58E-02
71	COL6A3	P12111	-1.36	6.65E-03
72	IL2RA	P01589	-1.35	1.07E-02
73	CDH5	P33151	-1.33	8.04E-03
74	CA3	P07451	-1.33	3.76E-02
75	IL1RL1	Q01638	-1.32	1.52E-02
76	JAM2	P57087	-1.31	3.38E-03
77	CXCL9	Q07325	-1.31	4.17E-02
78	CRTAC1	Q9NQ79	-1.3	2.57E-02
79	FOLR2	P14207	-1.3	6.18E-03
80	IL20RA	Q9UHF4	-1.29	1.13E-03
81	PPP1R2	P41236	-1.29	1.23E-02
82	PDGFRB	P09619	-1.29	7.97E-04
83	COMP	P49747	-1.28	1.22E-02
84	GUCA2A	Q02747	-1.28	2.89E-02
		•		

86 CTRC Q99895 -1.24 3.35E-02 87 IL18BP O95998 -1.23 3.11E-02 88 C2 P06681 -1.21 4.72E-02 89 CPB1 P15086 -1.21 4.98E-03 90 LILRB1 Q8NHL6 -1.18 2.30E-02 91 MARCO Q9UEW3 -1.18 2.13E-03 92 FST P19883 -1.18 2.13E-03 93 CNDP1 Q96KN2 -1.17 4.20E-02 94 CD70 P32970 -1.14 6.65E-03 95 KLRB1 Q12918 -1.14 5.83E-03 96 CDHR5 Q9HB88 -1.14 1.55E-04 97 SPON1 Q9HCB6 -1.13 3.13E-02 98 REG3A Q06141 -1.13 3.10E-02 99 CLEC14A Q86T13 -1.12 3.57E-02 100 CLC Q05315 -1.1 1.65E-02 101<
87 IL18BP 095998 -1.23 3.11E-02 88 C2 P06681 -1.21 4.72E-02 89 CPB1 P15086 -1.21 4.98E-03 90 LILRB1 Q8NHL6 -1.18 2.30E-02 91 MARCO Q9UEW3 -1.18 2.13E-03 92 FST P19883 -1.18 2.13E-03 93 CNDP1 Q96KN2 -1.17 4.20E-02 94 CD70 P32970 -1.14 6.65E-03 95 KLRB1 Q12918 -1.14 5.83E-03 96 CDHR5 Q9HB88 -1.14 1.55E-04 97 SPON1 Q9HCB6 -1.13 3.13E-02 98 REG3A Q06141 -1.13 3.10E-02 99 CLEC14A Q86T13 -1.12 3.57E-02 100 CLC Q05315 -1.1 1.65E-02 101 FAM3C Q92520 -1.1 2.92E-03 102
88 C2 P06681 -1.21 4.72E-02 89 CPB1 P15086 -1.21 4.98E-03 90 LILRB1 Q8NHL6 -1.18 2.30E-02 91 MARCO Q9UEW3 -1.18 2.23E-02 92 FST P19883 -1.18 2.13E-03 93 CNDP1 Q96KN2 -1.17 4.20E-02 94 CD70 P32970 -1.14 6.65E-03 95 KLRB1 Q12918 -1.14 5.83E-03 96 CDHR5 Q9HB88 -1.14 1.55E-04 97 SPON1 Q9HCB6 -1.13 3.13E-02 98 REG3A Q06141 -1.13 3.10E-02 99 CLEC14A Q86T13 -1.12 3.57E-02 100 CLC Q05315 -1.1 1.65E-02 101 FAM3C Q92520 -1.1 2.92E-03 102 CD6 P30203 -1.09 2.84E-02 103 </td
89CPB1P15086-1.214.98E-0390LILRB1Q8NHL6-1.182.30E-0291MARCOQ9UEW3-1.182.23E-0292FSTP19883-1.182.13E-0393CNDP1Q96KN2-1.174.20E-0294CD70P32970-1.146.65E-0395KLRB1Q12918-1.145.83E-0396CDHR5Q9HBB8-1.141.55E-0497SPON1Q9HCB6-1.133.13E-0298REG3AQ06141-1.133.10E-0299CLEC14AQ86T13-1.123.57E-02100CLCQ05315-1.11.65E-02101FAM3CQ92520-1.12.92E-03102CD6P30203-1.092.84E-02103WFIKKN2Q8TEU8-1.094.58E-02104FCN2Q15485-1.063.17E-02
90LILRB1Q8NHL6-1.182.30E-0291MARCOQ9UEW3-1.182.23E-0292FSTP19883-1.182.13E-0393CNDP1Q96KN2-1.174.20E-0294CD70P32970-1.146.65E-0395KLRB1Q12918-1.145.83E-0396CDHR5Q9HB88-1.141.55E-0497SPON1Q9HCB6-1.133.13E-0298REG3AQ06141-1.133.10E-0299CLEC14AQ86T13-1.123.57E-02100CLCQ05315-1.11.65E-03102CD6P30203-1.092.84E-02103WFIKKN2Q8TEU8-1.094.58E-02104FCN2Q15485-1.092.97E-02105IL13P35225-1.063.17E-02
91MARCOQ9UEW3-1.182.23E-0292FSTP19883-1.182.13E-0393CNDP1Q96KN2-1.174.20E-0294CD70P32970-1.146.65E-0395KLRB1Q12918-1.145.83E-0396CDHR5Q9HBB8-1.141.55E-0497SPON1Q9HCB6-1.133.13E-0298REG3AQ06141-1.133.10E-0299CLEC14AQ86T13-1.123.57E-02100CLCQ05315-1.11.65E-02101FAM3CQ92520-1.12.92E-03102CD6P30203-1.092.84E-02103WFIKKN2Q8TEU8-1.094.58E-02104FCN2Q15485-1.092.97E-02105IL13P35225-1.063.17E-02
92FSTP19883-1.182.13E-0393CNDP1Q96KN2-1.174.20E-0294CD70P32970-1.146.65E-0395KLRB1Q12918-1.145.83E-0396CDHR5Q9HBB8-1.141.55E-0497SPON1Q9HCB6-1.133.13E-0298REG3AQ06141-1.133.10E-0299CLEC14AQ86T13-1.123.57E-02100CLCQ05315-1.11.65E-02101FAM3CQ92520-1.12.92E-03102CD6P30203-1.092.84E-02103WFIKKN2Q8TEU8-1.094.58E-02104FCN2Q15485-1.092.97E-02105IL13P35225-1.063.17E-02
93CNDP1Q96KN2-1.174.20E-0294CD70P32970-1.146.65E-0395KLRB1Q12918-1.145.83E-0396CDHR5Q9HBB8-1.141.55E-0497SPON1Q9HCB6-1.133.13E-0298REG3AQ06141-1.133.10E-0299CLEC14AQ86T13-1.123.57E-02100CLCQ05315-1.11.65E-02101FAM3CQ92520-1.12.92E-03102CD6P30203-1.092.84E-02103WFIKKN2Q8TEU8-1.094.58E-02104FCN2Q15485-1.092.97E-02105IL13P35225-1.063.17E-02
94CD70P32970-1.146.65E-0395KLRB1Q12918-1.145.83E-0396CDHR5Q9HBB8-1.141.55E-0497SPON1Q9HCB6-1.133.13E-0298REG3AQ06141-1.133.10E-0299CLEC14AQ86T13-1.123.57E-02100CLCQ05315-1.11.65E-02101FAM3CQ92520-1.12.92E-03102CD6P30203-1.092.84E-02103WFIKKN2Q8TEU8-1.094.58E-02104FCN2Q15485-1.092.97E-02105IL13P35225-1.063.17E-02
95KLRB1Q12918-1.145.83E-0396CDHR5Q9HBB8-1.141.55E-0497SPON1Q9HCB6-1.133.13E-0298REG3AQ06141-1.133.10E-0299CLEC14AQ86T13-1.123.57E-02100CLCQ05315-1.11.65E-02101FAM3CQ92520-1.12.92E-03102CD6P30203-1.092.84E-02103WFIKKN2Q8TEU8-1.094.58E-02104FCN2Q15485-1.092.97E-02105IL13P35225-1.063.17E-02
96CDHR5Q9HBB8-1.141.55E-0497SPON1Q9HCB6-1.133.13E-0298REG3AQ06141-1.133.10E-0299CLEC14AQ86T13-1.123.57E-02100CLCQ05315-1.11.65E-02101FAM3CQ92520-1.12.92E-03102CD6P30203-1.092.84E-02103WFIKKN2Q8TEU8-1.094.58E-02104FCN2Q15485-1.092.97E-02105IL13P35225-1.063.17E-02
97SPON1Q9HCB6-1.133.13E-0298REG3AQ06141-1.133.10E-0299CLEC14AQ86T13-1.123.57E-02100CLCQ05315-1.11.65E-02101FAM3CQ92520-1.12.92E-03102CD6P30203-1.092.84E-02103WFIKKN2Q8TEU8-1.094.58E-02104FCN2Q15485-1.092.97E-02105IL13P35225-1.063.17E-02
98 REG3A Q06141 -1.13 3.10E-02 99 CLEC14A Q86T13 -1.12 3.57E-02 100 CLC Q05315 -1.1 1.65E-02 101 FAM3C Q92520 -1.1 2.92E-03 102 CD6 P30203 -1.09 2.84E-02 103 WFIKKN2 Q8TEU8 -1.09 4.58E-02 104 FCN2 Q15485 -1.09 2.97E-02 105 IL13 P35225 -1.06 3.17E-02
99 CLEC14A Q86T13 -1.12 3.57E-02 100 CLC Q05315 -1.1 1.65E-02 101 FAM3C Q92520 -1.1 2.92E-03 102 CD6 P30203 -1.09 2.84E-02 103 WFIKKN2 Q8TEU8 -1.09 4.58E-02 104 FCN2 Q15485 -1.09 2.97E-02 105 IL13 P35225 -1.06 3.17E-02
100CLCQ05315-1.11.65E-02101FAM3CQ92520-1.12.92E-03102CD6P30203-1.092.84E-02103WFIKKN2Q8TEU8-1.094.58E-02104FCN2Q15485-1.092.97E-02105IL13P35225-1.063.17E-02
101FAM3CQ92520-1.12.92E-03102CD6P30203-1.092.84E-02103WFIKKN2Q8TEU8-1.094.58E-02104FCN2Q15485-1.092.97E-02105IL13P35225-1.063.17E-02
102CD6P30203-1.092.84E-02103WFIKKN2Q8TEU8-1.094.58E-02104FCN2Q15485-1.092.97E-02105IL13P35225-1.063.17E-02
103 WFIKKN2 Q8TEU8 -1.09 4.58E-02 104 FCN2 Q15485 -1.09 2.97E-02 105 IL13 P35225 -1.06 3.17E-02
104 FCN2 Q15485 -1.09 2.97E-02 105 IL13 P35225 -1.06 3.17E-02
105 IL13 P35225 -1.06 3.17E-02
106 FABP2 P12104 -1.06 3.69E-02
107 VASN Q6EMK4 -1.06 3.21E-02
108 DPT Q07507 -1.05 1.01E-02
109 IGFBP1 P08833 -1.04 2.67E-03
110 TSHB P01222 -1.03 6.02E-03
111 RUVBL1 Q9Y265 -1.02 1.90E-02
112 CCL14 Q16627 -1.02 1.25E-02
113 REG1A P05451 -1.01 1.05E-02
114 NELL1 Q92832 -0.99 3.48E-02
115 COL4A1 P02462 -0.98 1.74E-02
116 PRDX5 P30044 -0.98 1.70E-03
117 PTGDS P41222 -0.98 3.59E-03
118 APOH P02749 -0.98 2.33E-03
119 FABP4 P15090 -0.97 2.95E-04
120 CD160 O95971 -0.97 4.59E-03
121 STC1 P52823 -0.97 3.64E-02
122 XPNPEP2 O43895 -0.95 1.37E-02
123 ACP5 P13686 -0.94 1.69E-02
124 OXT P01178 -0.93 2.76E-02
125 AXL P30530 -0.92 1.72E-02
126 CD22 P20273 -0.89 2.88E-02
127 ENPP2 Q13822 -0.88 2.23E-02
128 ADM P35318 -0.87 3.66E-02

129	PVALB	P20472	-0.86	2.38E-02
130	REG1B	P48304	-0.85	3.52E-02
131	CNTN3	Q9P232	-0.84	3.41E-02
132	PEAR1	Q5VY43	-0.84	1.21E-02
133	SPINK1	P00995	-0.82	2.87E-02
134	NRP1	014786	-0.79	1.30E-02
135	FASLG	P48023	-0.79	4.23E-02
136	CD300LF	Q8TDQ1	-0.79	4.28E-02
137	CFC1	P0CG37	-0.77	8.10E-03
138	CD27	P26842	-0.76	2.68E-02
139	VM01	Q7Z5L0	-0.73	4.61E-02
140	COL18A1	P39060	-0.72	4.52E-02
141	CNST	Q6PJW8	-0.71	1.46E-02
142	IL12RB1	P42701	-0.7	9.54E-03
143	CD79B	P40259	-0.69	3.46E-02
144	SCG2	P13521	-0.69	2.83E-02
145	CDH17	Q12864	-0.66	6.90E-03
146	PCDH1	Q08174	-0.65	6.29E-06
147	ICAM1	P05362	-0.65	2.91E-02
148	TNFSF11	014788	-0.63	8.27E-03
149	CD1C	P29017	-0.62	1.21E-03
150	CTSS	P25774	-0.6	4.85E-02
151	SFTPA2	Q8IWL1	-0.6	1.23E-02
152	CBLN4	Q9NTU7	-0.59	5.34E-03
153	VTCN1	Q7Z7D3	-0.58	3.64E-02
154	LGALS3	P17931	-0.57	3.21E-02
155	CD244	Q9BZW8	-0.56	2.00E-02
156	MIF	P14174	-0.54	3.59E-02
157	FLT4	P35916	-0.52	1.30E-02
158	CTSL	P07711	-0.52	4.39E-02

Supplementary table 4 – Proteins significantly upregulated by prednisolone versus placebo in sputum (Olink®)

	Assay	UniProt	Log2fold change	Adjusted p value
1	CES2	000748	2.35	2.65E-04
2	EREG	014944	1.98	4.81E-04
3	DEFB4A_DEFB4B	015263	1.73	2.56E-02
4	DKK4	Q9UBT3	1.65	1.41E-02
5	GP2	P55259	1.63	3.95E-06
6	CALB1	P05937	1.5	2.40E-02
7	TIMP3	P35625	1.44	1.51E-02
8	FKBP5	Q13451	1.43	3.29E-02
9	XG	P55808	1.4	7.96E-03
10	GFRA1	P56159	1.4	2.40E-03

11	NPPB	P16860	1.4	3.89E-02
12	CRNN	Q9UBG3	1.39	4.73E-03
13	PLAT	P00750	1.38	1.84E-02
14	KLK8	060259	1.38	1.75E-04
15	PLTP	P55058	1.35	2.48E-02
16	SLC27A4	Q6P1M0	1.33	1.46E-02
17	IL1B	P01584	1.32	2.59E-02
18	IL17C	Q9P0M4	1.28	3.11E-02
19	EPHA2	P29317	1.2	1.88E-02
20	NDRG1	Q92597	1.18	3.52E-03
21	ARID4B	Q4LE39	1.18	4.88E-02
22	DSG3	P32926	1.16	4.00E-05
23	PRSS27	Q9BQR3	1.15	1.75E-02
24	ANXA5	P08758	1.13	2.24E-03
25	CNTN5	094779	1.12	5.36E-03
26	SNCG	076070	1.11	2.89E-02
27	ULBP2	Q9BZM5	1.1	1.40E-02
28	WFDC12	Q8WWY7	1.08	5.30E-03
29	CEACAM21	Q3KPI0	1.05	3.74E-02
30	FCAR	P24071	1.03	4.54E-02
31	DSC2	Q02487	1.02	1.88E-03
32	SPINK5	Q9NQ38	0.99	1.37E-03
33	ADGRG2	Q8IZP9	0.97	4.27E-03
34	F2R	P25116	0.95	2.71E-04
35	CA12	043570	0.92	4.93E-02
36	KLK6	Q92876	0.92	4.97E-04
37	IVD	P26440	0.89	1.82E-04
38	CDSN	Q15517	0.87	3.62E-03
39	LDLR	P01130	0.83	3.69E-02
40	DNER	Q8NFT8	0.81	7.91E-03
41	PSMA1	P25786	0.78	1.73E-02
42	ESM1	Q9NQ30	0.78	5.11E-03
43	CHMP1A	Q9HD42	0.73	3.95E-03
44	HS3ST3B1	Q9Y662	0.72	6.73E-03
45	IL22RA1	Q8N6P7	0.67	8.90E-03
46	DCN	P07585	0.67	2.24E-02
47	PODXL2	Q9NZ53	0.6	2.95E-02
48	ACVRL1	P37023	0.59	3.96E-02
49	CTSV	060911	0.58	1.05E-02
50	KCNIP4	Q6PIL6	0.54	4.69E-02
51	PSG1	P11464	0.51	1.44E-02

	Assay	UniProt	Log2fold change	Adjusted p value
1	IL4	P05112	-3.17	1.06E-05
2	IL12A_IL12B	P29459_P29460	-2.24	1.55E-26
3	IL12B	P29460	-2.09	3.88E-26
4	CRH	P06850	-1.46	3.80E-11
5	CCL22	O00626	-1.42	4.18E-21
6	MMP12	P39900	-1.42	5.07E-14
7	CCL19	Q99731	-1.24	2.94E-14
8	TNFSF13B	Q9Y275	-0.94	1.03E-20
9	THBS4	P35443	-0.93	7.59E-08
10	FGF19	095750	-0.93	1.63E-02
11	GGH	Q92820	-0.91	9.66E-18
12	TNFRSF8	P28908	-0.91	1.67E-16
13	TNFRSF4	P43489	-0.91	3.98E-19
14	CCDC80	Q76M96	-0.9	1.29E-14
15	SIGLEC6	O43699	-0.86	2.87E-21
16	TNFRSF9	Q07011	-0.85	9.89E-14
17	CD83	Q01151	-0.84	4.03E-13
18	IFNG	P01579	-0.84	6.50E-03
19	CLEC4C	Q8WTT0	-0.81	5.93E-06
20	CCL18	P55774	-0.81	2.03E-08
21	CXCL10	P02778	-0.79	3.74E-09
22	CCL17	Q92583	-0.77	4.81E-11
23	PDCD1	Q15116	-0.77	2.35E-21
24	CCL26	Q9Y258	-0.75	4.31E-06
25	CCN3	P48745	-0.74	5.80E-10
26	CD207	Q9UJ71	-0.71	9.97E-09
27	OXT	P01178	-0.69	1.11E-04
28	ADAMTS8	Q9UP79	-0.68	4.01E-10
29	CR2	P20023	-0.66	1.47E-13
30	TPPP3	Q9BW30	-0.66	1.30E-04
31	DLK1	P80370	-0.66	1.06E-12
32	CD28	P10747	-0.66	1.73E-06
33	OMG	P23515	-0.65	8.41E-05
34	OGN	P20774	-0.65	4.84E-10
35	RET	P07949	-0.65	2.20E-13
36	IL6	P05231	-0.65	2.51E-03
37	CDON	Q4KMG0	-0.64	7.29E-12
38	PAEP	P09466	-0.64	3.66E-06
39	FOLR2	P14207	-0.64	3.48E-16
40	SMAD5	Q99717	-0.64	5.05E-10
41	CCL21	000585	-0.64	9.54E-10

Supplementary table 5 – Proteins significantly downregulated by prednisolone versus placebo in plasma (Olink[®])

42	CD70	P32970	-0.64	1.23E-10
43	CD300E	Q496F6	-0.63	6.27E-09
44	ITIH3	Q06033	-0.63	2.09E-08
45	CD1C	P29017	-0.62	2.26E-18
46	LAMP3	Q9UQV4	-0.62	6.56E-11
47	MARCO	Q9UEW3	-0.62	3.73E-18
48	DRAXIN	Q8NBI3	-0.62	5.19E-10
49	CD200R1	Q8TD46	-0.62	5.60E-14
50	MMP10	P09238	-0.61	8.08E-06
51	FASLG	P48023	-0.6	1.20E-16
52	GSTA3	Q16772	-0.6	4.09E-03
53	CXCL17	Q6UXB2	-0.59	1.16E-09
54	CDCP1	Q9H5V8	-0.59	5.35E-09
55	CD22	P20273	-0.59	3.33E-17
56	GZMB	P10144	-0.58	2.44E-04
57	MSR1	P21757	-0.57	2.37E-11
58	SERPINA9	Q86WD7	-0.56	1.39E-04
59	CNTN2	Q02246	-0.55	3.55E-11
60	LAG3	P18627	-0.54	1.43E-10
61	IFNL1	Q8IU54	-0.54	8.64E-05
62	KLK14	Q9P0G3	-0.54	1.79E-09
63	LTA	P01374	-0.54	2.19E-10
64	FCRL1	Q96LA6	-0.53	2.29E-14
65	CD79B	P40259	-0.53	3.69E-15
66	TNFRSF13B	O14836	-0.52	1.20E-14
67	ADAM23	075077	-0.52	1.43E-08
68	CXCL11	O14625	-0.51	2.10E-05
69	DPT	Q07507	-0.51	1.86E-10
70	LRRC25	Q8N386	-0.51	8.36E-09
71	COL1A1	P02452	-0.51	1.98E-07
72	COL6A3	P12111	-0.51	1.39E-08
73	VWC2	Q2TAL6	-0.5	1.71E-07
74	MDGA1	Q8NFP4	-0.5	6.67E-13

Supplementary table 6 – Proteins significantly upregulated by prednisolone versus placebo in plasma (Olink[®])

	Assay	UniProt	Log2fold change	Adjusted p value
1	MMP3	P08254	2.29	1.21E-28
2	ZBTB16	Q05516	1.88	5.02E-14
3	IL10	P22301	1.63	1.98E-06
4	GCG	P01275	1.41	3.93E-06
5	PFKFB2	060825	1.41	7.54E-06
6	AREG	P15514	1.37	8.78E-12
7	FKBP5	Q13451	1.3	1.72E-03

8	GP2	P55259	1.16	3.41E-09
9	MATN3	015232	1.03	9.59E-15
10	TMPRSS15	P98073	0.98	2.01E-04
11	TNFAIP8	095379	0.9	4.60E-02
12	SERPINA12	Q8IW75	0.89	5.98E-09
13	AGR3	Q8TD06	0.87	3.16E-03
14	OSM	P13725	0.86	8.28E-05
15	TGFA	P01135	0.85	1.10E-05
16	STAT5B	P51692	0.82	9.60E-04
17	VSIG4	Q9Y279	0.82	6.29E-13
18	IL1RL1	Q01638	0.81	7.26E-13
19	CD177	Q8N6Q3	0.79	9.72E-09
20	CST7	076096	0.76	7.01E-08
21	RBP2	P50120	0.75	5.11E-04
22	NAMPT	P43490	0.74	3.06E-03
23	MFGE8	Q08431	0.73	2.38E-10
24	PADI2	Q9Y2J8	0.68	8.22E-06
25	IL17C	Q9P0M4	0.68	6.68E-03
26	SLC39A5	Q6ZMH5	0.67	7.27E-11
27	CEACAM8	P31997	0.65	4.45E-04
28	CLPS	P04118	0.64	1.69E-06
29	PIK3AP1	Q6ZUJ8	0.63	6.57E-03
30	IPCEF1	Q8WWN9	0.63	2.71E-02
31	MMP8	P22894	0.63	8.89E-04
32	SCP2	P22307	0.61	1.17E-03
33	PADI4	Q9UM07	0.61	1.09E-02
34	PROK1	P58294	0.6	8.48E-05
35	RGMA	Q96B86	0.6	8.78E-14
36	CES1	P23141	0.6	1.43E-04
37	PM20D1	Q6GTS8	0.59	4.24E-06
38	HCLS1	P14317	0.58	4.08E-03
39	MME	P08473	0.58	1.34E-07
40	MMP9	P14780	0.57	1.44E-05
41	ARG1	P05089	0.55	3.25E-03
42	CCL20	P78556	0.55	4.47E-02
43	CCL15	Q16663	0.55	2.16E-07
44	RASSF2	P50749	0.55	3.90E-02
45	LEP	P41159	0.54	4.29E-04
46	CEP43	095684	0.54	3.13E-03
47	REN	P00797	0.53	9.54E-07
48	MVK	Q03426	0.53	2.45E-03
49	PROC	P04070	0.53	3.80E-10
50	YTHDF3	Q7Z739	0.52	8.40E-03
51	FEN1	P39748	0.51	2.17E-02

52	BAIAP2	Q9UQB8	0.51	1.57E-03
53	DNAJB1	P25685	0.5	1.15E-02

Supplementary table 7 – The effect of prednisolone versus placebo on sputum proteins (ELISA)

Assay	Change in protein	Log2fold change	Adjusted p value
117/25		-0.40	0.41
(ng/ml)	-1.05	-0.40	0.41
	0.658	0.014	0.08
(ng/ml)	0.058	0.014	0.98
(Pg/111) 11 1 R	-24.2	-0.18	0.50
(ng/ml)	-24.2	-0.18	0.55
	12 5	0.24	0.57
ILZNA	-12.5	-0.24	0.37
(Pg/111)	_1 /	-0.056	0.80
(ng/ml)	-1.4	-0.050	0.89
(122	-1.61	-0.25	0.45
(ng/ml)	-1.01	-0.25	0.45
(P8/111)	3 15	0.23	0.61
(ng/ml)	5.15	0.25	0.01
	13.6	0.18	0.67
(ng/ml)	+5.0	0.10	0.07
MPO	833	0.89	0.27
(ng/ml)	000	0.05	0.27
VKI 40	-19.6	-0.57	0.52
(ng/ml)	19.0	0.07	0.02
IL1Ra	16.9	1.00	0.045
(ng/ml)			
GMCSF	0.022	0.46	0.45
(pg/ml)			
TSLP	1.25	1.30	0.37
(pg/ml)			
EDN	-1181	-1.04	0.0001
(ng/ml)			
IL1R1	222	0.51	0.125
(pg/ml)			

	Log2fold	Adjusted p value	Gene
	change		
1	-2.93	7.42E-02	CXCL5
2	-2.88	9.25E-02	SRARP
3	-2.69	5.47E-02	TNFAIP6
4	-2.62	8.88E-02	GNAO1
5	-2.55	8.43E-02	IGLC2
6	-2.41	5.37E-02	MMP12
7	-2.38	2.84E-02	ADCYAP1
8	-2.03	2.84E-02	CXCL3
9	-1.96	2.84E-02	HOXB2
10	-1.80	2.84E-02	TPSB2
11	-1.75	5.47E-02	CXCL2
12	-1.73	2.84E-02	LGI1
13	-1.73	9.97E-02	AC016868.1
14	-1.71	2.84E-02	FCGBP
15	-1.67	9.27E-02	CD48
16	-1.64	3.32E-02	ADRA2A
17	-1.54	2.84E-02	B3GNT6
18	-1.45	2.84E-02	PPP1R16B
19	-1.43	3.30E-02	CX3CR1
20	-1.38	5.04E-02	DUSP2
21	-1.37	2.84E-02	GSDMD
22	-1.33	2.84E-02	C3
23	-1.21	9.37E-02	BPIFA1
24	-1.12	9.37E-02	CYR61
25	-0.91	7.29E-02	FER1L6
26	-0.91	5.47E-02	HIPK2
27	-0.90	2.84E-02	ALOX15
28	-0.83	5.37E-02	HDAC9
29	0.71	2.84E-02	RBP1
30	0.71	9.37E-02	ALOX15B
31	1.44	2.84E-02	PANK4

Supplementary table 8 - The effect of prednisolone versus placebo on nasal tissue gene transcription

Supplementary table 9 – Precursor miRNA significantly differentially expressed by prednisolone versus placebo

Pre-cursor miRNA	Difference	Adjusted p value
	in	

		normalised	
		gene count	
1	hsa-mir-6511a-3	-58.8	0.00252
2	hsa-mir-6511a-2	-58.8	0.00252
3	hsa-mir-6511a-1	-58.8	0.00252
4	hsa-mir-6511a-4	-58.8	0.00252
5	hsa-mir-516a-1	111	0.00592
6	hsa-mir-516a-2	111	0.00592
7	hsa-mir-5701-2	-77.5	0.0114
8	hsa-mir-5701-3	-77.5	0.0114
9	hsa-mir-5701-1	-77.5	0.0114
10	hsa-mir-518a-2	-84.4	0.0405
11	hsa-mir-518a-1	-84.4	0.0405
12	hsa-mir-3670-2	24.0	0.0448
13	hsa-mir-3670-4	24.0	0.0448
14	hsa-mir-3670-3	24.0	0.0448
15	hsa-mir-3670-1	24.0	0.0448
16	hsa-mir-4520-1	44.9	0.0687
17	hsa-mir-4520-2	39.9	0.0687
18	hsa-mir-4650-2	-30.9	0.0930
19	hsa-mir-4650-1	-30.9	0.0930

Supplementary table 10 – Nasal tissue genes significantly downregulated by mepolizumab

	Log2fold change	Adjusted p	Gene
		value	
1	-1.38	3.05E-03	CROCC2
2	-1.05	3.05E-03	KCNH3
3	-1.17	3.05E-03	HMCN2
4	-1.17	7.35E-03	BEST4
5	-0.84	7.90E-03	KNDC1
6	-1.03	9.41E-03	HAGHL
7	-0.85	1.32E-02	GRIN3B
8	-0.87	1.36E-02	BAIAP3
9	-1.04	1.41E-02	CFAP65
10	-0.94	1.56E-02	WDR97
11	-0.82	1.56E-02	RHPN1
12	-0.65	1.58E-02	MUC16
13	-1.54	1.58E-02	MAPK15
14	-0.90	1.58E-02	RSPH14
15	-1.70	1.60E-02	LKAAEAR1
16	-1.28	1.60E-02	TGFBR3L
17	-0.97	1.87E-02	TTLL10
18	-0.83	1.87E-02	CD164L2
19	-1.11	1.87E-02	CCDC114

20	-0.99	1.87E-02	SPEF1
21	-1.00	1.87E-02	CDHR4
22	-0.98	1.88E-02	DLEC1
23	-0.97	1.88E-02	DNAI1
24	-0.97	1.90E-02	DNAI2
25	-0.64	1.96E-02	SCGB2A1
26	-1.55	1.97E-02	RNF31
27	-1.01	1.97E-02	ZFHX2
28	-0.99	2.01E-02	LRRC46
29	-1.11	2.04E-02	PPP1R32
30	-0.92	2.09E-02	TEKT2
31	-1.01	2.11E-02	STK33
32	-0.87	2.11E-02	CCDC153
33	-0.82	2.11E-02	NAT14
34	-1.42	2.11E-02	FAM95C
35	-0.90	2.23E-02	RFX2
36	-1.54	2.35E-02	FAM238C
37	-0.91	2.35E-02	UBXN11
38	-1.13	2.38E-02	JPH3
39	-0.73	2.54E-02	WDR90
40	-0.89	2.54E-02	DENND6B
41	-1.01	2.54E-02	CATIP
42	-0.83	2.55E-02	ZNF473
43	-1.15	2.55E-02	LRRC74B
44	-0.96	2.55E-02	LRRC23
45	-0.91	2.60E-02	MAP6
46	-0.72	2.60E-02	HSD11B1L
47	-0.63	2.60E-02	WDR34
48	-0.94	2.77E-02	RNFT2
49	-1.03	2.82E-02	CCDC151
50	-0.73	2.91E-02	DNER
51	-0.81	3.01E-02	ODF3B
52	-1.32	3.04E-02	TNNI3
53	-0.90	3.04E-02	FAM92B
54	-1.27	3.11E-02	SERPINI2
55	-0.97	3.11E-02	TCTEX1D4
56	-0.95	3.11E-02	LRRC71
57	-0.89	3.12E-02	RSPH9
58	-0.89	3.12E-02	CCDC78
59	-0.95	3.27E-02	FNDC11
60	-1.19	3.27E-02	PCSK1N
61	-0.61	3.27E-02	PPP1R16A
62	-0.86	3.28E-02	MORN1
63	-1.15	3.28E-02	HHATL-AS1
L		1	

64	-1.30	3.28E-02	TTLL6
65	-0.99	3.33E-02	DNAAF1
66	-0.74	3.33E-02	PRUNE2
67	-0.91	3.33E-02	C21orf58
68	-0.98	3.33E-02	C2orf70
69	-1.22	3.33E-02	AC004836.1
70	-1.03	3.33E-02	TMC4
71	-0.71	3.33E-02	ANKMY1
72	-0.94	3.33E-02	PCSK4
73	-1.22	3.33E-02	SYT5
74	-0.54	3.36E-02	SPPL2B
75	-0.94	3.38E-02	CCDC13
76	-0.91	3.41E-02	LINC02166
77	-0.68	3.42E-02	SSBP4
78	-0.86	3.42E-02	TTC21A
79	-1.65	3.42E-02	DOC2A
80	-0.87	3.42E-02	ZMYND10
81	-0.97	3.45E-02	CCDC162P
82	-1.38	3.48E-02	MUC12
83	-0.91	3.50E-02	DNAAF3
84	-1.11	3.50E-02	SSUH2
85	-1.02	3.50E-02	DZIP1L
86	-2.24	3.50E-02	U62317.1
87	-0.75	3.50E-02	ENKD1
88	-1.02	3.53E-02	TMEM52
89	-1.20	3.56E-02	SQSTM1
90	-0.91	3.57E-02	KIF19
91	-0.89	3.57E-02	FAM183A
92	-1.01	3.57E-02	SPAG8
93	-0.96	3.57E-02	DRC1
94	-0.84	3.70E-02	GOLGA2P5
95	-1.04	3.70E-02	AC027281.1
96	-1.01	3.72E-02	CRIP1
97	-0.82	3.76E-02	CCDC17
98	-0.84	3.76E-02	LRRC10B
99	-0.69	3.76E-02	GAS8
100	-0.92	3.76E-02	CFAP73
101	-0.81	3.76E-02	OSCP1
102	-0.89	3.76E-02	TBC1D9B
103	-0.61	3.76E-02	ZNF688
104	-1.01	3.76E-02	AC010754.1
105	-0.85	3.98E-02	DRC3
106	-0.89	4.15E-02	GPR162
107	-0.59	4.18E-02	ZNHIT2
L	1	1	1

109 -0.87 4.23E-02 WDR54 110 -0.88 4.31E-02 TTC25 111 -0.70 4.36E-02 LRRC61 112 -0.91 4.40E-02 C2orf40 113 -0.79 4.48E-02 GiPR 114 -0.88 4.56E-02 C1orf89 115 -1.11 4.69E-02 C1orf87 117 -0.69 4.69E-02 CFAP99 118 -0.91 4.69E-02 CFAP99 119 -0.85 4.69E-02 CFAP100 120 -0.73 4.72E-02 PSENEN 121 -0.80 4.72E-02 PR7 122 -0.74 4.72E-02 WHRN 123 -0.68 4.72E-02 WHRN 126 -0.69 4.72E-02 WHRN 126 -0.69 4.72E-02 WHRN 127 -0.62 4.80E-02 MZF1 128 -0.95 4.86E-02 NPR2 130<	108	-1.00	4.19E-02	CFAP74
110 -0.88 4.31E-02 TTC25 111 -0.70 4.36E-02 LRRC61 112 -0.91 4.40E-02 C2orf40 113 -0.79 4.48E-02 GIPR 114 -0.88 4.56E-02 C1orf189 115 -1.11 4.69E-02 FABP6 116 -0.76 4.69E-02 MAPK8IP1 118 -0.91 4.69E-02 CFAP99 119 -0.85 4.69E-02 CFAP100 120 -0.73 4.72E-02 PSENEN 121 -0.80 4.72E-02 PR7 122 -0.74 4.72E-02 GALNS 124 -0.89 4.72E-02 WHRN 125 -0.64 4.72E-02 WHRN 126 -0.69 4.72E-02 WHRN 127 -0.62 4.86E-02 MZF1 128 -0.95 4.86E-02 NPR2 130 -0.89 4.87E-02 CFAP157	109	-0.87	4.23E-02	WDR54
111 -0.70 4.36E-02 LRRC61 112 -0.91 4.40E-02 C2orf40 113 -0.79 4.48E-02 GIPR 114 -0.88 4.56E-02 C1orf189 115 -1.11 4.69E-02 FABP6 116 -0.76 4.69E-02 C1orf87 117 -0.69 4.69E-02 CFAP99 118 -0.91 4.69E-02 CFAP100 120 -0.73 4.72E-02 PSENEN 121 -0.80 4.72E-02 PR7 122 -0.74 4.72E-02 GALNS 123 -0.68 4.72E-02 WHRN 124 -0.89 4.72E-02 WHRN 125 -0.64 4.72E-02 WHRN 126 -0.69 4.72E-02 WHRN 127 -0.62 4.80E-02 MZF1 128 -0.95 4.86E-02 NPR2 130 -0.87 4.94E-02 LRRC73 131	110	-0.88	4.31E-02	TTC25
112 -0.91 4.40E-02 C2orf40 113 -0.79 4.48E-02 GIPR 114 -0.88 4.56E-02 C1orf189 115 -1.11 4.69E-02 FABP6 116 -0.76 4.69E-02 C1orf87 117 -0.69 4.69E-02 CFAP99 118 -0.91 4.69E-02 CFAP100 120 -0.73 4.72E-02 PSENEN 121 -0.80 4.72E-02 PSENEN 122 -0.74 4.72E-02 TPP3 123 -0.68 4.72E-02 GALNS 124 -0.89 4.72E-02 WHRN 126 -0.69 4.72E-02 WHRN 126 -0.69 4.72E-02 WHRN 127 -0.62 4.86E-02 MPF2 130 -0.89 4.86E-02 NPR2 131 -0.87 4.94E-02 LRRC73 132 -1.13 4.95E-02 CD180 1	111	-0.70	4.36E-02	LRRC61
113 -0.79 4.48E-02 GIPR 114 -0.88 4.56E-02 C1orf189 115 -1.11 4.69E-02 FABP6 116 -0.76 4.69E-02 C1orf87 117 -0.69 4.69E-02 CAPP99 118 -0.91 4.69E-02 CFAP100 120 -0.73 4.72E-02 PSENEN 121 -0.80 4.72E-02 PRR7 122 -0.74 4.72E-02 GALNS 124 -0.89 4.72E-02 GALNS 125 -0.64 4.72E-02 WHRN 126 -0.69 4.72E-02 WHRN 126 -0.69 4.72E-02 WHRN 126 -0.69 4.72E-02 MZF1 128 -0.95 4.86E-02 MZF1 128 -0.95 4.86E-02 NPR2 130 -0.89 4.92E-02 LRRC73 131 -0.87 4.94E-02 LRRC43 133<	112	-0.91	4.40E-02	C2orf40
114 -0.88 4.56E-02 Clorf189 115 -1.11 4.69E-02 FABP6 116 -0.76 4.69E-02 Clorf87 117 -0.69 4.69E-02 CAPP99 118 -0.91 4.69E-02 CFAP99 119 -0.85 4.69E-02 CFAP100 120 -0.73 4.72E-02 PSENEN 121 -0.80 4.72E-02 PRR7 122 -0.74 4.72E-02 GALNS 124 -0.89 4.72E-02 GALNS 124 -0.89 4.72E-02 WHRN 125 -0.64 4.72E-02 WHRN 126 -0.69 4.72E-02 UCN3 127 -0.62 4.80E-02 MZF1 128 -0.95 4.86E-02 NPR2 130 -0.89 4.37E-02 CCDC180 131 -0.87 4.94E-02 LRRC73 132 -1.13 4.95E-02 CEK14 133 -0.94 4.95E-02 CD180 133 -0.94	113	-0.79	4.48E-02	GIPR
115 -1.11 4.69E-02 FABP6 116 -0.76 4.69E-02 Clorf87 117 -0.69 4.69E-02 MAPK8IP1 118 -0.91 4.69E-02 CFAP99 119 -0.85 4.69E-02 CFAP100 120 -0.73 4.72E-02 PSENEN 121 -0.80 4.72E-02 PRR7 122 -0.74 4.72E-02 GALNS 124 -0.89 4.72E-02 GALNS 125 -0.64 4.72E-02 WHRN 126 -0.69 4.72E-02 UCN3 127 -0.62 4.80E-02 MZF1 128 -0.95 4.86E-02 NPR2 130 -0.89 4.87E-02 CFAP157 131 -0.87 4.94E-02 LRRC73 132 -1.13 4.95E-02 CDC180 133 -0.94 4.95E-02 CLDN9 136 -0.83 5.10E-02 CDN3	114	-0.88	4.56E-02	C1orf189
116 -0.76 4.69E-02 C1orf87 117 -0.69 4.69E-02 MAPK8IP1 118 -0.91 4.69E-02 CFAP99 119 -0.85 4.69E-02 CFAP100 120 -0.73 4.72E-02 PSENEN 121 -0.80 4.72E-02 PRR7 122 -0.74 4.72E-02 GALNS 124 -0.89 4.72E-02 GALNS 125 -0.64 4.72E-02 WHRN 126 -0.69 4.72E-02 WCN3 127 -0.62 4.80E-02 MZF1 128 -0.95 4.86E-02 NPR2 130 -0.89 4.87E-02 CFAP157 131 -0.87 4.94E-02 LRRC73 132 -1.13 4.95E-02 TEKT4 134 -0.97 4.95E-02 CDN9 135 -1.35 5.02E-02 CLDN9 136 -0.83 5.10E-02 CLDN3 1	115	-1.11	4.69E-02	FABP6
117 -0.69 4.69E-02 MAPK8IP1 118 -0.91 4.69E-02 CFAP99 119 -0.85 4.69E-02 CFAP100 120 -0.73 4.72E-02 PSENEN 121 -0.80 4.72E-02 PRR7 122 -0.74 4.72E-02 GALNS 124 -0.89 4.72E-02 GALNS 124 -0.89 4.72E-02 WHRN 126 -0.64 4.72E-02 WHRN 126 -0.69 4.72E-02 WCN3 127 -0.62 4.80E-02 MZF1 128 -0.95 4.86E-02 NPR2 130 -0.89 4.87E-02 CFAP157 131 -0.87 4.94E-02 LRRC73 132 -1.13 4.95E-02 TEKT4 134 -0.97 4.95E-02 CLDN9 135 -1.35 5.02E-02 CLDN3 138 -0.94 5.12E-02 GAS2L2 13	116	-0.76	4.69E-02	C1orf87
118 -0.91 4.69E-02 CFAP99 119 -0.85 4.69E-02 CFAP100 120 -0.73 4.72E-02 PSENEN 121 -0.80 4.72E-02 PRR7 122 -0.74 4.72E-02 TPPP3 123 -0.68 4.72E-02 GALNS 124 -0.89 4.72E-02 WHRN 125 -0.64 4.72E-02 WHRN 126 -0.69 4.72E-02 UCN3 127 -0.62 4.80E-02 MZF1 128 -0.95 4.86E-02 NPR2 130 -0.89 4.87E-02 CFAP157 131 -0.87 4.94E-02 LRRC73 132 -1.13 4.95E-02 TEKT4 134 -0.97 4.95E-02 CDN9 135 -1.35 5.02E-02 CLDN9 136 -0.83 5.10E-02 CLDN3 138 -0.94 5.12E-02 GAS2L2 139 <td>117</td> <td>-0.69</td> <td>4.69E-02</td> <td>MAPK8IP1</td>	117	-0.69	4.69E-02	MAPK8IP1
119 -0.85 4.69E-02 CFAP100 120 -0.73 4.72E-02 PSENEN 121 -0.80 4.72E-02 PRR7 122 -0.74 4.72E-02 TPPP3 123 -0.68 4.72E-02 GALNS 124 -0.89 4.72E-02 EFCAB12 125 -0.64 4.72E-02 WHRN 126 -0.69 4.72E-02 UCN3 127 -0.62 4.80E-02 MZF1 128 -0.95 4.86E-02 NPR2 130 -0.89 4.87E-02 CFAP157 131 -0.87 4.94E-02 LRRC73 132 -1.13 4.95E-02 TEKT4 134 -0.97 4.95E-02 CD180 133 -0.94 4.95E-02 LRC43 135 -1.35 5.02E-02 CLDN3 136 -0.83 5.10E-02 CLDN3 138 -0.94 5.12E-02 GAS2L2 139	118	-0.91	4.69E-02	CFAP99
120 -0.73 4.72E-02 PSENEN 121 -0.80 4.72E-02 PRR7 122 -0.74 4.72E-02 TPPP3 123 -0.68 4.72E-02 GALNS 124 -0.89 4.72E-02 GALNS 125 -0.64 4.72E-02 WHRN 126 -0.69 4.72E-02 UCN3 127 -0.62 4.80E-02 MZF1 128 -0.95 4.86E-02 NPR2 130 -0.89 4.87E-02 CFAP157 131 -0.87 4.94E-02 LRRC73 132 -1.13 4.95E-02 CCDC180 133 -0.94 4.95E-02 TEKT4 134 -0.97 4.95E-02 LRRC43 135 -1.35 5.02E-02 CLDN9 136 -0.83 5.10E-02 CLDN3 137 -0.64 5.10E-02 MORN5 140 -0.99 5.13E-02 MCN 142 <td>119</td> <td>-0.85</td> <td>4.69E-02</td> <td>CFAP100</td>	119	-0.85	4.69E-02	CFAP100
121 -0.80 4.72E-02 PRR7 122 -0.74 4.72E-02 TPPP3 123 -0.68 4.72E-02 GALNS 124 -0.89 4.72E-02 EFCAB12 125 -0.64 4.72E-02 WHRN 126 -0.69 4.72E-02 UCN3 127 -0.62 4.80E-02 MZF1 128 -0.95 4.86E-02 NPR2 130 -0.89 4.87E-02 CFAP157 131 -0.87 4.94E-02 LRRC73 132 -1.13 4.95E-02 CCDC180 133 -0.94 4.95E-02 LRRC43 135 -1.35 5.02E-02 LRRC43 135 -1.35 5.02E-02 CLDN9 136 -0.83 5.10E-02 CLNN1 137 -0.64 5.10E-02 GAS2L2 139 -0.81 5.13E-02 MORN5 140 -0.99 5.13E-02 MCN 142<	120	-0.73	4.72E-02	PSENEN
122 -0.74 4.72E-02 TPPP3 123 -0.68 4.72E-02 GALNS 124 -0.89 4.72E-02 EFCAB12 125 -0.64 4.72E-02 WHRN 126 -0.69 4.72E-02 WCN3 127 -0.62 4.80E-02 MZF1 128 -0.95 4.86E-02 NPR2 130 -0.89 4.87E-02 CFAP157 131 -0.87 4.94E-02 LRRC73 132 -1.13 4.95E-02 CCDC180 133 -0.94 4.95E-02 TEKT4 134 -0.97 4.95E-02 LRRC43 135 -1.35 5.02E-02 CLDN9 136 -0.83 5.10E-02 CLDN3 138 -0.94 5.12E-02 GAS2L2 139 -0.81 5.13E-02 MORN5 140 -0.99 5.13E-02 KNCN 142 -0.81 5.13E-02 AL357093.1 <t< td=""><td>121</td><td>-0.80</td><td>4.72E-02</td><td>PRR7</td></t<>	121	-0.80	4.72E-02	PRR7
123 -0.68 4.72E-02 GALNS 124 -0.89 4.72E-02 EFCAB12 125 -0.64 4.72E-02 WHRN 126 -0.69 4.72E-02 UCN3 127 -0.62 4.80E-02 MZF1 128 -0.95 4.86E-02 HHLA2 129 -0.98 4.86E-02 NPR2 130 -0.89 4.87E-02 CFAP157 131 -0.87 4.94E-02 LRRC73 132 -1.13 4.95E-02 CCDC180 133 -0.94 4.95E-02 TEKT4 134 -0.97 4.95E-02 LRRC43 135 -1.35 5.02E-02 CLDN9 136 -0.83 5.10E-02 CLDN3 138 -0.94 5.12E-02 GAS2L2 139 -0.81 5.13E-02 MORN5 140 -0.99 5.13E-02 KNCN 142 -0.81 5.13E-02 KNCN 142 -0.81 5.13E-02 AQP10 145 -0.94	122	-0.74	4.72E-02	TPPP3
124-0.894.72E-02EFCAB12125-0.644.72E-02WHRN126-0.694.72E-02UCN3127-0.624.80E-02MZF1128-0.954.86E-02NPR2130-0.894.87E-02CFAP157131-0.874.94E-02LRRC73132-1.134.95E-02CCDC180133-0.944.95E-02LRRC43135-1.355.02E-02CLDN9136-0.835.10E-02CLDN9137-0.645.10E-02CLDN3138-0.945.12E-02GAS2L2139-0.815.13E-02TTC16141-2.135.13E-02KNCN142-0.815.13E-02CAorf47144-1.395.19E-02C4orf47144-0.795.32E-02C4orf47146-0.795.37E-02LDLRAD1147-0.875.43E-02CFAP46148-0.895.51E-02WDR38149-0.695.60E-02MAPRE3150-0.785.80E-02DNAH2	123	-0.68	4.72E-02	GALNS
125-0.644.72E-02WHRN126-0.694.72E-02UCN3127-0.624.80E-02MZF1128-0.954.86E-02HHLA2129-0.984.86E-02NPR2130-0.894.87E-02CFAP157131-0.874.94E-02LRRC73132-1.134.95E-02CCDC180133-0.944.95E-02TEKT4134-0.974.95E-02CLDN9136-0.835.10E-02CTXN1137-0.645.10E-02CLDN3138-0.945.12E-02GAS2L2139-0.815.13E-02MORN5140-0.995.13E-02KNCN142-0.815.13E-02KNCN144-1.395.19E-02AQP10145-0.945.32E-02C4orf47146-0.795.37E-02LDLRAD1147-0.875.43E-02WDR38149-0.695.60E-02MAPRE3150-0.785.80E-02CYP2F1151-0.795.80E-02DNAH2	124	-0.89	4.72E-02	EFCAB12
126-0.694.72E-02UCN3127-0.624.80E-02MZF1128-0.954.86E-02NPR2130-0.894.87E-02CFAP157131-0.874.94E-02LRRC73132-1.134.95E-02CCDC180133-0.944.95E-02LRRC43134-0.974.95E-02CLDN9136-0.835.10E-02CTXN1137-0.645.10E-02CLDN3138-0.945.12E-02GAS2L2139-0.815.13E-02TTC16141-2.135.13E-02KNCN142-0.815.13E-02AL357093.1144-1.395.19E-02AQP10145-0.945.32E-02C4orf47146-0.795.37E-02LDLRAD1147-0.875.43E-02WDR38149-0.695.60E-02MAPRE3150-0.785.80E-02CYP2F1151-0.795.80E-02DNAH2	125	-0.64	4.72E-02	WHRN
127-0.624.80E-02MZF1128-0.954.86E-02HHLA2129-0.984.86E-02NPR2130-0.894.87E-02CFAP157131-0.874.94E-02LRRC73132-1.134.95E-02CCDC180133-0.944.95E-02TEKT4134-0.974.95E-02LRRC43135-1.355.02E-02CLDN9136-0.835.10E-02CTXN1137-0.645.10E-02CLDN3138-0.945.12E-02GAS2L2139-0.815.13E-02MORN5140-0.995.13E-02KNCN142-0.815.13E-02KNCN143-1.425.13E-02AL357093.1144-1.395.19E-02AQP10145-0.945.32E-02C4orf47146-0.795.37E-02LDLRAD1147-0.875.43E-02CFAP46148-0.895.51E-02WDR38149-0.695.60E-02MAPRE3150-0.785.80E-02CYP2F1151-0.795.80E-02DNAH2	126	-0.69	4.72E-02	UCN3
128-0.954.86E-02HHLA2129-0.984.86E-02NPR2130-0.894.87E-02CFAP157131-0.874.94E-02LRRC73132-1.134.95E-02CCDC180133-0.944.95E-02TEKT4134-0.974.95E-02LRRC43135-1.355.02E-02CLDN9136-0.835.10E-02CTXN1137-0.645.10E-02CLDN3138-0.945.12E-02GAS2L2139-0.815.13E-02MORN5140-0.995.13E-02KNCN142-0.815.13E-02KNCN143-1.425.13E-02AL357093.1144-1.395.19E-02AQP10145-0.945.32E-02C4orf47146-0.795.37E-02LDLRAD1147-0.875.43E-02CFAP46148-0.895.51E-02WDR38149-0.695.60E-02MAPRE3150-0.785.80E-02CYP2F1151-0.795.80E-02DNAH2	127	-0.62	4.80E-02	MZF1
129-0.984.86E-02NPR2130-0.894.87E-02CFAP157131-0.874.94E-02LRRC73132-1.134.95E-02CCDC180133-0.944.95E-02TEKT4134-0.974.95E-02LRRC43135-1.355.02E-02CLDN9136-0.835.10E-02CLDN3138-0.945.12E-02GAS2L2139-0.645.13E-02MORN5140-0.995.13E-02TTC16141-2.135.13E-02KNCN142-0.815.13E-02EFCAB1143-1.425.13E-02AQP10144-1.395.19E-02AQP10145-0.945.32E-02C4orf47146-0.795.37E-02LDLRAD1147-0.875.43E-02CFAP46148-0.895.51E-02WDR38149-0.695.60E-02MAPRE3150-0.785.80E-02CYP2F1151-0.795.80E-02DNAH2	128	-0.95	4.86E-02	HHLA2
130-0.894.87E-02CFAP157131-0.874.94E-02LRRC73132-1.134.95E-02CCDC180133-0.944.95E-02TEKT4134-0.974.95E-02LRRC43135-1.355.02E-02CLDN9136-0.835.10E-02CTXN1137-0.645.10E-02CLDN3138-0.945.12E-02GAS2L2139-0.815.13E-02MORN5140-0.995.13E-02TTC16141-2.135.13E-02KNCN142-0.815.13E-02AL357093.1144-1.395.19E-02AQP10145-0.945.32E-02C4orf47146-0.795.37E-02LDLRAD1147-0.875.43E-02CFAP46148-0.895.51E-02WDR38149-0.695.60E-02MAPRE3150-0.785.80E-02CYP2F1151-0.795.80E-02DNAH2	129	-0.98	4.86E-02	NPR2
131-0.874.94E-02LRRC73132-1.134.95E-02CCDC180133-0.944.95E-02TEKT4134-0.974.95E-02LRRC43135-1.355.02E-02CLDN9136-0.835.10E-02CTXN1137-0.645.10E-02GAS2L2139-0.815.13E-02MORN5140-0.995.13E-02TTC16141-2.135.13E-02KNCN142-0.815.13E-02EFCAB1143-1.425.13E-02AL357093.1144-1.395.19E-02AQP10145-0.945.32E-02C4orf47146-0.795.37E-02LDLRAD1147-0.875.43E-02CFAP46148-0.895.51E-02WDR38149-0.695.60E-02MAPRE3150-0.785.80E-02CYP2F1151-0.795.80E-02DNAH2	130	-0.89	4.87E-02	CFAP157
132-1.134.95E-02CCDC180133-0.944.95E-02TEKT4134-0.974.95E-02LRRC43135-1.355.02E-02CLDN9136-0.835.10E-02CTXN1137-0.645.10E-02CLDN3138-0.945.12E-02GAS2L2139-0.815.13E-02MORN5140-0.995.13E-02TTC16141-2.135.13E-02KNCN142-0.815.13E-02EFCAB1143-1.425.13E-02AQP10144-1.395.19E-02AQP10145-0.945.32E-02C4orf47146-0.795.37E-02LDLRAD1147-0.875.43E-02CFAP46148-0.895.51E-02WDR38149-0.695.60E-02MAPRE3150-0.785.80E-02CYP2F1151-0.795.80E-02DNAH2	131	-0.87	4.94E-02	LRRC73
133-0.944.95E-02TEKT4134-0.974.95E-02LRRC43135-1.355.02E-02CLDN9136-0.835.10E-02CTXN1137-0.645.10E-02CLDN3138-0.945.12E-02GAS2L2139-0.815.13E-02MORN5140-0.995.13E-02TTC16141-2.135.13E-02KNCN142-0.815.13E-02EFCAB1143-1.425.13E-02AL357093.1144-1.395.19E-02AQP10145-0.945.32E-02C4orf47146-0.795.37E-02LDLRAD1147-0.875.43E-02CFAP46148-0.895.51E-02WDR38149-0.695.60E-02MAPRE3150-0.785.80E-02CYP2F1151-0.795.80E-02DNAH2	132	-1.13	4.95E-02	CCDC180
134-0.974.95E-02LRRC43135-1.355.02E-02CLDN9136-0.835.10E-02CTXN1137-0.645.10E-02GAS2L2138-0.945.12E-02GAS2L2139-0.815.13E-02MORN5140-0.995.13E-02TTC16141-2.135.13E-02KNCN142-0.815.13E-02EFCAB1143-1.425.13E-02AL357093.1144-1.395.19E-02AQP10145-0.945.32E-02C4orf47146-0.795.37E-02LDLRAD1147-0.875.43E-02CFAP46148-0.895.51E-02WDR38149-0.695.60E-02MAPRE3150-0.785.80E-02CYP2F1151-0.795.80E-02DNAH2	133	-0.94	4.95E-02	TEKT4
135-1.355.02E-02CLDN9136-0.835.10E-02CTXN1137-0.645.10E-02CLDN3138-0.945.12E-02GAS2L2139-0.815.13E-02MORN5140-0.995.13E-02TTC16141-2.135.13E-02KNCN142-0.815.13E-02EFCAB1143-1.425.13E-02AL357093.1144-1.395.19E-02AQP10145-0.945.32E-02C4orf47146-0.795.37E-02LDLRAD1147-0.875.43E-02CFAP46148-0.895.51E-02WDR38149-0.695.60E-02MAPRE3150-0.785.80E-02CYP2F1151-0.795.80E-02DNAH2	134	-0.97	4.95E-02	LRRC43
136-0.835.10E-02CTXN1137-0.645.10E-02CLDN3138-0.945.12E-02GAS2L2139-0.815.13E-02MORN5140-0.995.13E-02TTC16141-2.135.13E-02KNCN142-0.815.13E-02EFCAB1143-1.425.13E-02AL357093.1144-1.395.19E-02AQP10145-0.945.32E-02C4orf47146-0.795.37E-02LDLRAD1147-0.875.43E-02CFAP46148-0.895.51E-02WDR38149-0.695.60E-02MAPRE3150-0.785.80E-02CYP2F1151-0.795.80E-02DNAH2	135	-1.35	5.02E-02	CLDN9
137-0.645.10E-02CLDN3138-0.945.12E-02GAS2L2139-0.815.13E-02MORN5140-0.995.13E-02TTC16141-2.135.13E-02KNCN142-0.815.13E-02EFCAB1143-1.425.13E-02AL357093.1144-1.395.19E-02AQP10145-0.945.32E-02C4orf47146-0.795.37E-02LDLRAD1147-0.875.43E-02CFAP46148-0.895.51E-02WDR38149-0.695.60E-02MAPRE3150-0.785.80E-02CYP2F1151-0.795.80E-02DNAH2	136	-0.83	5.10E-02	CTXN1
138-0.945.12E-02GAS2L2139-0.815.13E-02MORN5140-0.995.13E-02TTC16141-2.135.13E-02KNCN142-0.815.13E-02EFCAB1143-1.425.13E-02AL357093.1144-1.395.19E-02AQP10145-0.945.32E-02C4orf47146-0.795.37E-02LDLRAD1147-0.875.43E-02CFAP46148-0.895.51E-02WDR38149-0.695.60E-02MAPRE3150-0.785.80E-02CYP2F1151-0.795.80E-02DNAH2	137	-0.64	5.10E-02	CLDN3
139-0.815.13E-02MORN5140-0.995.13E-02TTC16141-2.135.13E-02KNCN142-0.815.13E-02EFCAB1143-1.425.13E-02AL357093.1144-1.395.19E-02AQP10145-0.945.32E-02C4orf47146-0.795.37E-02LDLRAD1147-0.875.43E-02CFAP46148-0.895.51E-02WDR38149-0.695.60E-02MAPRE3150-0.785.80E-02CYP2F1151-0.795.80E-02DNAH2	138	-0.94	5.12E-02	GAS2L2
140-0.995.13E-02TTC16141-2.135.13E-02KNCN142-0.815.13E-02EFCAB1143-1.425.13E-02AL357093.1144-1.395.19E-02AQP10145-0.945.32E-02C4orf47146-0.795.37E-02LDLRAD1147-0.875.43E-02CFAP46148-0.895.51E-02WDR38149-0.695.60E-02MAPRE3150-0.785.80E-02CYP2F1151-0.795.80E-02DNAH2	139	-0.81	5.13E-02	MORN5
141-2.135.13E-02KNCN142-0.815.13E-02EFCAB1143-1.425.13E-02AL357093.1144-1.395.19E-02AQP10145-0.945.32E-02C4orf47146-0.795.37E-02LDLRAD1147-0.875.43E-02CFAP46148-0.895.51E-02WDR38149-0.695.60E-02MAPRE3150-0.785.80E-02CYP2F1151-0.795.80E-02DNAH2	140	-0.99	5.13E-02	TTC16
142-0.815.13E-02EFCAB1143-1.425.13E-02AL357093.1144-1.395.19E-02AQP10145-0.945.32E-02C4orf47146-0.795.37E-02LDLRAD1147-0.875.43E-02CFAP46148-0.895.51E-02WDR38149-0.695.60E-02MAPRE3150-0.785.80E-02CYP2F1151-0.795.80E-02DNAH2	141	-2.13	5.13E-02	KNCN
143-1.425.13E-02AL357093.1144-1.395.19E-02AQP10145-0.945.32E-02C4orf47146-0.795.37E-02LDLRAD1147-0.875.43E-02CFAP46148-0.895.51E-02WDR38149-0.695.60E-02MAPRE3150-0.785.80E-02CYP2F1151-0.795.80E-02DNAH2	142	-0.81	5.13E-02	EFCAB1
144-1.395.19E-02AQP10145-0.945.32E-02C4orf47146-0.795.37E-02LDLRAD1147-0.875.43E-02CFAP46148-0.895.51E-02WDR38149-0.695.60E-02MAPRE3150-0.785.80E-02CYP2F1151-0.795.80E-02DNAH2	143	-1.42	5.13E-02	AL357093.1
145-0.945.32E-02C4orf47146-0.795.37E-02LDLRAD1147-0.875.43E-02CFAP46148-0.895.51E-02WDR38149-0.695.60E-02MAPRE3150-0.785.80E-02CYP2F1151-0.795.80E-02DNAH2	144	-1.39	5.19E-02	AQP10
146-0.795.37E-02LDLRAD1147-0.875.43E-02CFAP46148-0.895.51E-02WDR38149-0.695.60E-02MAPRE3150-0.785.80E-02CYP2F1151-0.795.80E-02DNAH2	145	-0.94	5.32E-02	C4orf47
147-0.875.43E-02CFAP46148-0.895.51E-02WDR38149-0.695.60E-02MAPRE3150-0.785.80E-02CYP2F1151-0.795.80E-02DNAH2	146	-0.79	5.37E-02	LDLRAD1
148-0.895.51E-02WDR38149-0.695.60E-02MAPRE3150-0.785.80E-02CYP2F1151-0.795.80E-02DNAH2	147	-0.87	5.43E-02	CFAP46
149-0.695.60E-02MAPRE3150-0.785.80E-02CYP2F1151-0.795.80E-02DNAH2	148	-0.89	5.51E-02	WDR38
150 -0.78 5.80E-02 CYP2F1 151 -0.79 5.80E-02 DNAH2	149	-0.69	5.60E-02	MAPRE3
151 -0.79 5.80E-02 DNAH2	150	-0.78	5.80E-02	CYP2F1
	151	-0.79	5.80E-02	DNAH2

152	-0.97	5.86E-02	Mar-10
153	-1.04	5.86E-02	SLC7A2
154	-0.84	5.86E-02	C1orf228
155	-0.87	5.86E-02	CDHR3
156	-0.87	5.86E-02	DNAH6
157	-0.99	5.86E-02	AL121899.1
158	-1.47	5.89E-02	VWA3A
159	-0.77	5.89E-02	AK8
160	-0.81	5.91E-02	CROCC
161	-0.83	5.93E-02	RSPH1
162	-0.85	5.98E-02	CFAP45
163	-0.84	5.98E-02	MAP1A
164	-0.63	5.98E-02	CCDC24
165	-0.85	5.98E-02	C20orf85
166	-0.83	6.04E-02	AL031283.1
167	-0.75	6.06E-02	CCDC96
168	-0.83	6.06E-02	IQCD
169	-1.09	6.19E-02	AC073439.1
170	-0.86	6.22E-02	RAB36
171	-0.75	6.25E-02	SRGAP3-AS2
172	-0.77	6.28E-02	C9orf24
173	-1.15	6.40E-02	AC104809.1
174	-0.83	6.40E-02	IQCA1
175	-0.82	6.43E-02	CCDC74A
176	-0.78	6.43E-02	CCDC33
177	-0.56	6.43E-02	RPRM
178	-1.63	6.54E-02	CRISP2
179	-0.50	6.56E-02	LRRC45
180	-0.83	6.57E-02	C1orf194
181	-0.82	6.65E-02	CFAP54
182	-0.59	6.69E-02	TMEM234
183	-1.05	6.76E-02	AC113349.1
184	-0.86	6.76E-02	TUBA4B
185	-0.83	6.78E-02	CFAP52
186	-1.12	6.81E-02	PTCH2
187	-0.82	6.85E-02	RIIAD1
188	-0.84	6.88E-02	C11orf88
189	-0.63	6.88E-02	AC073335.2
190	-0.72	7.06E-02	CD38
191	-1.28	7.06E-02	MAT1A
192	-0.71	7.06E-02	IQCN
193	-0.58	7.06E-02	COPRS
194	-0.69	7.22E-02	WDR66
195	-0.80	7.27E-02	SPEF2
L	1	1	1

196	-1.61	7.27E-02	ARSEP1
197	-1.02	7.30E-02	ALG1L8P
198	-0.86	7.36E-02	SCARF2
199	-0.84	7.36E-02	NHLRC4
200	-0.87	7.41E-02	NME9
201	-0.92	7.44E-02	C11orf16
202	-0.77	7.56E-02	CABCOCO1
203	-0.77	7.60E-02	KLHDC9
204	-0.82	7.62E-02	MAATS1
205	-0.90	7.67E-02	RBM24
206	-0.91	7.75E-02	C1orf158
207	-0.97	7.83E-02	UMODL1-AS1
208	-0.53	7.83E-02	RAD9A
209	-0.52	7.83E-02	ZDHHC1
210	-1.40	7.83E-02	Mar-04
211	-0.54	7.93E-02	ADPRHL2
212	-0.68	7.93E-02	TUBB4B
213	-0.84	8.16E-02	PRR29
214	-1.04	8.20E-02	CCDC184
215	-0.64	8.21E-02	METTL27
216	-0.79	8.24E-02	FANK1
217	-1.61	8.30E-02	FAM120B
218	-0.95	8.30E-02	FAM227A
219	-0.51	8.42E-02	MGAT3
220	-0.83	8.47E-02	CCDC30
221	-0.75	8.47E-02	LRRC27
222	-0.77	8.47E-02	C9orf116
223	-1.21	8.47E-02	DCAF11
224	-0.63	8.47E-02	C21orf59
225	-0.74	8.56E-02	NPHP1
226	-0.80	8.56E-02	DNAH12
227	-0.57	8.57E-02	P4HTM
228	-0.78	8.59E-02	DNAH9
229	-1.05	8.72E-02	KLHDC7B
230	-0.79	8.86E-02	TUBA1A
231	-0.54	8.87E-02	СКВ
232	-0.86	8.88E-02	CFAP161
233	-0.59	8.90E-02	ANKK1
234	-0.88	8.93E-02	TSPAN19
235	-0.79	8.93E-02	CCDC157
236	-1.17	8.94E-02	AC116562.3
237	-0.78	8.95E-02	TSNAXIP1
238	-0.70	9.02E-02	РРОХ
239	-0.73	9.02E-02	PACRG
L	1	1	l .

240	-1.07	9.02E-02	ZNF295-AS1
241	-0.51	9.02E-02	MED25
242	-0.63	9.10E-02	ANKRD54
243	-0.66	9.14E-02	WDR19
244	-0.82	9.24E-02	TOGARAM2
245	-1.05	9.24E-02	LRRIQ1
246	-0.83	9.24E-02	CAPS
247	-0.62	9.24E-02	ORAI2
248	-0.79	9.26E-02	MS4A8
249	-0.89	9.27E-02	PTPRT
250	-1.01	9.27E-02	AL645924.1
251	-0.78	9.30E-02	CAPSL
252	-0.66	9.34E-02	TCTN1
253	-0.82	9.35E-02	NEK5
254	-0.83	9.54E-02	FOXJ1
255	-0.92	9.63E-02	TTLL9
256	-0.64	9.63E-02	NPM2
257	-0.64	9.64E-02	CETN2
258	-0.70	9.64E-02	CFAP57
259	-0.69	9.64E-02	POMT2
260	-0.81	9.64E-02	CCDC189
261	-0.80	9.64E-02	EFHC1
262	-0.75	9.64E-02	RIBC1
263	-0.67	9.64E-02	CBY1
264	-0.79	9.69E-02	C5orf49
265	-0.67	9.80E-02	ICA1L
266	-0.80	9.80E-02	VPS28
267	-0.59	9.80E-02	FBXW9
268	-0.97	9.80E-02	ENO4
269	-1.14	9.80E-02	AL353747.3
270	-0.94	9.80E-02	C22orf15
271	-0.66	9.80E-02	DPCD
272	-0.78	9.80E-02	KIF24

Supplementary table 11 - Nasal tissue genes significantly upregulated by mepolizumab

	Log2fold	Adjusted p	Gene
	change	value	
1	4.88	2.00E-02	KRT14
2	4.14	3.00E-02	LIPK
3	3.85	1.00E-02	KRT16P6
4	3.84	1.00E-02	LIPG
5	3.76	7.00E-02	KRT16
6	3.7	4.00E-02	SPRR1B
7	3.54	0.00E+00	LUM
8	3.2	4.00E-02	KRT6A
9	2.97	3.00E-02	CXCL5
10	2.96	2.00E-02	NES
11	2.87	3.00E-02	LPL
12	2.84	1.00E-02	PDGFRB
13	2.55	0.00E+00	COL5A3
14	2.52	4.00E-02	KLK14
15	2.51	2.00E-02	NNMT
16	2.46	0.00E+00	EREG
17	2.43	1.00E-02	TGM1
18	2.4	1.00E-02	COL6A3
19	2.39	3.00E-02	SFRP2
20	2.33	2.00E-02	HCAR3
21	2.11	4.00E-02	COL1A2
22	2.06	0.00E+00	SPARC
23	2.01	7.00E-02	SLC25A24
24	1.98	4.00E-02	OLR1
25	1.9	9.00E-02	MMP19
26	1.89	6.00E-02	S100A12
27	1.83	1.00E-02	FOSL1
28	1.81	3.00E-02	DCN
29	1.77	0.00E+00	IL19
30	1.77	3.00E-02	GJB6
31	1.76	8.00E-02	DUSP9
32	1.75	4.00E-02	TINF2
33	1.74	6.00E-02	S100A2
34	1.74	4.00E-02	MCM10
35	1.73	0.00E+00	GJB2
36	1.73	7.00E-02	DOC2B
37	1.66	4.00E-02	PTHLH
38	1.64	7.00E-02	ELOVL4
39	1.62	0.00E+00	MYBL2
40	1.59	5.00E-02	KRT16P2
41	1.56	0.00E+00	RRM2

42	1.55	2.00E-02	MRC1
43	1.54	0.00E+00	SLC7A5
44	1.53	6.00E-02	GOLGA7B
45	1.53	1.00E-02	FOSB
46	1.5	0.00E+00	KRT17
47	1.47	3.00E-02	SERPINB7
48	1.47	0.00E+00	EGR1
49	1.44	6.00E-02	VSIG4
50	1.43	6.00E-02	EXO1
51	1.39	4.00E-02	COL6A2
52	1.38	2.00E-02	HBEGF
53	1.38	2.00E-02	C5AR2
54	1.37	0.00E+00	THBD
55	1.28	4.00E-02	ADAMTSL4
56	1.26	5.00E-02	CEMIP
57	1.22	5.00E-02	CDC45
58	1.21	4.00E-02	PBK
59	1.2	5.00E-02	IL1R2
60	1.2	5.00E-02	LZTS1
61	1.18	9.00E-02	ANGPTL4
62	1.18	2.00E-02	CEP55
63	1.15	6.00E-02	TIMP3
64	1.13	4.00E-02	CDC6
65	1.1	1.00E-01	FAM126A
66	1.09	9.00E-02	BIRC5
67	1.09	8.00E-02	SOCS3
68	1.06	8.00E-02	AMOTL1
69	1.05	4.00E-02	ADM
70	1.05	8.00E-02	ABCA12
71	1.01	8.00E-02	MMP2
72	0.98	5.00E-02	FSCN1
73	0.95	9.00E-02	TPX2
74	0.95	1.00E-02	LGALS7
75	0.93	5.00E-02	MXD1
76	0.92	9.00E-02	C1S
77	0.9	5.00E-02	GINS2
78	0.89	1.00E-02	PLAU
79	0.88	1.00E-02	FLNA
80	0.88	3.00E-02	DUSP7
81	0.88	6.00E-02	AKR1B10
82	0.88	1.00E-02	SERPINB4
83	0.00	8 00F-02	CALD1
1	0.86	0.001 02	0, 120 1
84	0.85	9.00E-02	NDRG1

86	0.81	2.00E-02	JUNB
87	0.8	6.00E-02	TK1
88	0.78	6.00E-02	FERMT1
89	0.76	2.00E-02	MCM6
90	0.76	4.00E-02	MDFI
91	0.76	6.00E-02	TCN1
92	0.75	4.00E-02	OSMR
93	0.74	7.00E-02	TINAGL1
94	0.71	5.00E-02	LDHA
95	0.7	6.00E-02	CD44
96	0.69	3.00E-02	ZFP36
97	0.69	4.00E-02	DAB2
98	0.68	3.00E-02	STMN1
99	0.68	5.00E-02	PTGS2
100	0.67	3.00E-02	NFKBIA
101	0.66	7.00E-02	TPM4
102	0.61	8.00E-02	FAM83D
103	0.58	5.00E-02	SIRPA
104	0.57	6.00E-02	MSN
105	0.53	7.00E-02	AKR1C2

Appendix

Summaries of RASP-UK standard operating procedures for sputum induction, nasal scrape sampling, and sputum processing in the MAPLE trial are as follows:

Sputum induction



*Start rescue procedure in section 4.7

^SRe-measure vital signs. Compare to pre-induction values. If stable, procedure is finished. If not, re-measure in 10 minutes. If still not stable, consult with PI/medic.

Nasal scrape sampling

- 1. Under direct visual inspection, insert cupped probe into the mid- inferior portion of the inferior turbinate.
- 2. Gently press the cupped tip on mucosal surface and move outwards 2-3mm (from only one nostril). Repeat motion 2-3 times. If the first scrape does not provide a visible sample, a second scrape should be done on the same nostril. If a second scrape is performed, the cells should be added to the same RNA protect as the first scrape. Make sure the second scrape is not traumatic.
- 3. The nasal cytology curette can be bent on an angle for ease of use.
- 4. Add 500µl of RNA protect cell reagent into an 2mL RNAse/DNAse-free cryovial.
- 5. Dip the curette into the cryovial containing RNA protect reagent. Lightly shake to free the sample from the curette. Discard the used curette.
- 6. Store samples at -80°C until shipment to central laboratory .

Sputum processing

